U.S. patent number 10,966,916 [Application Number 16/120,681] was granted by the patent office on 2021-04-06 for personal care compositions.
This patent grant is currently assigned to The Procter and Gamble Company. The grantee listed for this patent is The Procter & Gamble Company. Invention is credited to Karl Shiqing Wei.
![](/patent/grant/10966916/US10966916-20210406-D00000.png)
![](/patent/grant/10966916/US10966916-20210406-D00001.png)
![](/patent/grant/10966916/US10966916-20210406-D00002.png)
![](/patent/grant/10966916/US10966916-20210406-D00003.png)
![](/patent/grant/10966916/US10966916-20210406-D00004.png)
![](/patent/grant/10966916/US10966916-20210406-D00005.png)
![](/patent/grant/10966916/US10966916-20210406-D00006.png)
United States Patent |
10,966,916 |
Wei |
April 6, 2021 |
Personal care compositions
Abstract
A personal care composition includes a structured cleansing
phase; a benefit phase including triglycerides, a cationic
deposition polymer, and anionic microcapsules; and a carrier; and
methods relating thereto.
Inventors: |
Wei; Karl Shiqing (Mason,
OH) |
Applicant: |
Name |
City |
State |
Country |
Type |
The Procter & Gamble Company |
Cincinnati |
OH |
US |
|
|
Assignee: |
The Procter and Gamble Company
(Cincinnati, OH)
|
Family
ID: |
1000005467179 |
Appl.
No.: |
16/120,681 |
Filed: |
September 4, 2018 |
Prior Publication Data
|
|
|
|
Document
Identifier |
Publication Date |
|
US 20200069560 A1 |
Mar 5, 2020 |
|
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
14937089 |
Nov 10, 2015 |
10085924 |
|
|
|
62077899 |
Nov 10, 2014 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K
8/11 (20130101); A61K 8/737 (20130101); A61K
8/463 (20130101); A61K 8/922 (20130101); A61K
8/442 (20130101) |
Current International
Class: |
A61K
8/00 (20060101); A61K 8/44 (20060101); A61K
8/11 (20060101); A61K 8/73 (20060101); A61K
8/46 (20060101); A61K 8/92 (20060101) |
References Cited
[Referenced By]
U.S. Patent Documents
|
|
|
RE3300 |
February 1869 |
McGill |
RE3315 |
March 1869 |
Merrill |
2020454 |
November 1935 |
Spaulding |
2438091 |
March 1948 |
Lynch |
2528378 |
October 1950 |
Mannheimer et al. |
2658072 |
November 1953 |
Kosmin |
2798053 |
July 1957 |
Brown |
2986271 |
May 1961 |
Forrer |
3455440 |
July 1969 |
West |
3479429 |
November 1969 |
Morshauser |
3533955 |
October 1970 |
Pader |
3542256 |
November 1970 |
Waterman |
D220248 |
March 1971 |
Blumenthal |
3618757 |
November 1971 |
Funkhouser |
3800898 |
April 1974 |
Griffin |
3850365 |
November 1974 |
Dietrich |
3852475 |
December 1974 |
Tarangul |
3899076 |
August 1975 |
Florian |
3915921 |
October 1975 |
Schlatzer, Jr. |
3926861 |
December 1975 |
Gerecht |
3929678 |
December 1975 |
Laughlin et al. |
3937811 |
February 1976 |
Papantoniou |
3940351 |
February 1976 |
Schlatzer, Jr. |
3951679 |
April 1976 |
Bernhard |
3980767 |
September 1976 |
Chown |
4062817 |
December 1977 |
Westerman |
4159028 |
June 1979 |
Barker |
4263363 |
April 1981 |
Buck |
4335103 |
June 1982 |
Barker |
4379753 |
April 1983 |
Bolich, Jr. |
4384096 |
May 1983 |
Sonnabend |
4421902 |
December 1983 |
Chang |
4425322 |
January 1984 |
Harvey |
4429097 |
January 1984 |
Chang et al. |
4514552 |
April 1985 |
Shay |
4518578 |
May 1985 |
Hayes |
4600761 |
July 1986 |
Ruffner |
4616074 |
October 1986 |
Ruffner |
D292879 |
November 1987 |
Smith |
4743698 |
May 1988 |
Ruffner |
4772427 |
September 1988 |
Dawson |
4814160 |
March 1989 |
Carter |
4879114 |
November 1989 |
Catsimpoolas |
4966205 |
October 1990 |
Tanaka |
4980155 |
December 1990 |
Shah |
5002680 |
March 1991 |
Schmidt |
5011681 |
April 1991 |
Ciotti et al. |
5059414 |
October 1991 |
Dallal |
5104646 |
April 1992 |
Bolich, Jr. |
5106609 |
April 1992 |
Bolich, Jr. |
5135748 |
August 1992 |
Ziegler |
5147576 |
September 1992 |
Montague et al. |
5223315 |
June 1993 |
Katsura |
5228912 |
July 1993 |
Herget |
5292843 |
March 1994 |
Jenkins |
5294692 |
March 1994 |
Barron |
5304334 |
April 1994 |
Lahanas |
5342883 |
August 1994 |
Jenkins |
5364617 |
November 1994 |
Bush et al. |
5393450 |
February 1995 |
Shana |
5412142 |
May 1995 |
Wilkerson |
5455035 |
October 1995 |
Guerrero |
5462963 |
October 1995 |
Bush et al. |
5487168 |
January 1996 |
Geiner |
5487884 |
January 1996 |
Bissett et al. |
5523619 |
June 1996 |
Mcallister |
5540853 |
July 1996 |
Trinh |
5556628 |
September 1996 |
Derian |
5578299 |
November 1996 |
Starch |
5612307 |
March 1997 |
Chambers |
5632420 |
May 1997 |
Lohrman |
5635171 |
June 1997 |
Nadaud |
5652228 |
July 1997 |
Bissett |
5661189 |
August 1997 |
Grieveson |
5681852 |
October 1997 |
Bissett |
5687779 |
November 1997 |
Andersson |
5716920 |
February 1998 |
Glenn, Jr. |
5770760 |
June 1998 |
Robinson |
5816451 |
October 1998 |
Renault |
5851978 |
December 1998 |
Shana |
5873494 |
February 1999 |
Dallas, Jr. |
5874495 |
February 1999 |
Robinson |
5914117 |
June 1999 |
Lavaud |
5916575 |
June 1999 |
Mcatee |
5925603 |
July 1999 |
D |
5929019 |
July 1999 |
Puvvada |
5947335 |
September 1999 |
Milio |
5952286 |
September 1999 |
Puvvada |
5954213 |
September 1999 |
Gerhart |
5965500 |
October 1999 |
Puvvada |
5965501 |
October 1999 |
Rattinger |
5965502 |
October 1999 |
Balzer |
5972361 |
October 1999 |
Fowler |
6051386 |
April 2000 |
Lerner |
6068834 |
May 2000 |
Kvalnes et al. |
D426158 |
June 2000 |
Underwood |
6150312 |
November 2000 |
Puvvada et al. |
6150313 |
November 2000 |
Harmalker et al. |
6165395 |
December 2000 |
Kieras |
6174845 |
January 2001 |
Rattinger |
6176391 |
January 2001 |
Rehkemper |
6190648 |
February 2001 |
Kouzu |
6194364 |
February 2001 |
Glenn, Jr. |
D438460 |
March 2001 |
Hammond |
D439165 |
March 2001 |
Erckelbout |
6213166 |
April 2001 |
Thibiant |
6217888 |
April 2001 |
Oblong et al. |
D441645 |
May 2001 |
Longhurst |
6232496 |
May 2001 |
Carr |
6245323 |
June 2001 |
Christie |
6245344 |
June 2001 |
Thibiant |
6268322 |
July 2001 |
St. Lewis |
D446121 |
August 2001 |
Maddy |
6270446 |
August 2001 |
Abelbeck |
D448678 |
October 2001 |
Bakic |
6306806 |
October 2001 |
St. Lewis |
6335312 |
January 2002 |
Coffindaffer |
6338855 |
January 2002 |
Albacarys |
6340723 |
January 2002 |
Nitta |
D455655 |
April 2002 |
Bunce |
6367519 |
April 2002 |
Thibiant |
6383999 |
May 2002 |
Coyle |
6385992 |
May 2002 |
Flore, Jr. |
6394323 |
May 2002 |
Mcclean |
6395691 |
May 2002 |
Tsaur |
6407044 |
June 2002 |
Dixon |
6413192 |
July 2002 |
Abelbeck |
6419783 |
July 2002 |
Rainey |
6426326 |
July 2002 |
Mitra |
6429177 |
August 2002 |
Williams |
6433061 |
August 2002 |
Marchant et al. |
D467807 |
December 2002 |
Bakic |
6495498 |
December 2002 |
Niemiec |
6506391 |
January 2003 |
Biatry |
6516838 |
February 2003 |
Thibiant |
6517939 |
February 2003 |
Moini |
6521216 |
February 2003 |
Glandorf |
6523457 |
February 2003 |
Ancona |
6534456 |
March 2003 |
Hayward |
6534457 |
March 2003 |
Mitra |
6534458 |
March 2003 |
Kakizawa |
6537527 |
March 2003 |
Kvalnes et al. |
6547063 |
April 2003 |
Zaveri |
6555509 |
April 2003 |
Abbas et al. |
6564978 |
May 2003 |
Safian |
6574985 |
June 2003 |
Fiore, Jr. |
6589509 |
July 2003 |
Keller |
6635702 |
October 2003 |
Schmucker-Castner et al. |
6645511 |
November 2003 |
Aronson et al. |
6652134 |
November 2003 |
Lloyd |
6663855 |
December 2003 |
Frechet |
6673371 |
January 2004 |
Brown |
6673755 |
January 2004 |
Wei |
D486398 |
February 2004 |
Lovell |
6691394 |
February 2004 |
Mcclean |
6695510 |
February 2004 |
Look |
6716440 |
April 2004 |
Aronson |
6723688 |
April 2004 |
Malik |
6727209 |
April 2004 |
Pereira |
6759376 |
July 2004 |
Zhang et al. |
6780826 |
August 2004 |
Zhang et al. |
6849584 |
February 2005 |
Geary et al. |
D502400 |
March 2005 |
Cinquino |
D505079 |
May 2005 |
Mulder |
6897253 |
May 2005 |
Schmucker-Castner et al. |
6919303 |
July 2005 |
Pham |
6924256 |
August 2005 |
Massaro |
D525872 |
August 2006 |
Haubert |
D525873 |
August 2006 |
Haubert |
7084104 |
August 2006 |
Martin et al. |
7098180 |
August 2006 |
Ganopolsky et al. |
D527637 |
September 2006 |
Bakic |
D528005 |
September 2006 |
Bakic |
D529388 |
October 2006 |
Bakic |
D529810 |
October 2006 |
Davies |
7119059 |
October 2006 |
Librizzi et al. |
D533784 |
December 2006 |
Bakic |
7143893 |
December 2006 |
Kelly |
7144542 |
December 2006 |
Holzer |
7157414 |
January 2007 |
Librizzi et al. |
7229486 |
June 2007 |
Wiersema |
7229778 |
June 2007 |
Hendrix |
7268104 |
September 2007 |
Krzysik |
7273837 |
September 2007 |
Boutique |
7288616 |
October 2007 |
Tamareselvy |
7354926 |
April 2008 |
Lintner |
7488707 |
February 2009 |
Frantz et al. |
7511003 |
March 2009 |
Focht et al. |
7524807 |
April 2009 |
Clapp |
7527077 |
May 2009 |
McCall et al. |
7531497 |
May 2009 |
Midha et al. |
7537819 |
May 2009 |
Hendricks |
D601425 |
October 2009 |
Miller |
D601648 |
October 2009 |
Comello, Jr. |
D608648 |
January 2010 |
Rhodes |
7649047 |
January 2010 |
Tamareselvy et al. |
7666825 |
February 2010 |
Wagner et al. |
7737104 |
June 2010 |
Hilliard, Jr. |
7749951 |
July 2010 |
Hilliard, Jr. |
7754666 |
July 2010 |
Walters et al. |
7754667 |
July 2010 |
Walters |
7761242 |
July 2010 |
Honkonen |
7763419 |
July 2010 |
Hendrix et al. |
7767389 |
August 2010 |
Hendrix et al. |
7771924 |
August 2010 |
Hendrix et al. |
7771925 |
August 2010 |
Hendrix et al. |
7776346 |
August 2010 |
Oconnor |
7803403 |
September 2010 |
Librizzi |
7820609 |
October 2010 |
Soffin |
7906475 |
March 2011 |
Walters |
7954392 |
June 2011 |
Belcher |
D641633 |
July 2011 |
Carnduff |
D644106 |
August 2011 |
Almstead, Jr. |
8025902 |
September 2011 |
Librizzi |
D646170 |
October 2011 |
Carnduff |
8029772 |
October 2011 |
Frantz |
8067517 |
November 2011 |
Yoshinaka et al. |
8093192 |
January 2012 |
Liu |
8105996 |
January 2012 |
Wei et al. |
8124064 |
February 2012 |
Wei |
8124573 |
February 2012 |
Focht |
8147853 |
April 2012 |
Taylor |
8158566 |
April 2012 |
Wei |
D660181 |
May 2012 |
Nowacek |
D660704 |
May 2012 |
Simmons |
D660705 |
May 2012 |
Simmons |
8283852 |
October 2012 |
Lee |
8309667 |
November 2012 |
Yoshinaka et al. |
D674282 |
January 2013 |
Baldridge |
D674292 |
January 2013 |
Klich |
8394361 |
March 2013 |
Frantz |
8417474 |
April 2013 |
Datta |
D683226 |
May 2013 |
Baldridge |
8518991 |
August 2013 |
Gunn |
8772212 |
July 2014 |
Restrepo et al. |
8785397 |
July 2014 |
Bernard |
8795679 |
August 2014 |
Einarsson |
8840871 |
September 2014 |
Wei |
9101551 |
August 2015 |
Stella |
9162085 |
October 2015 |
Dihora et al. |
9186642 |
November 2015 |
Dihora |
9216143 |
December 2015 |
Restrepo et al. |
9352289 |
May 2016 |
Beijne et al. |
9671410 |
June 2017 |
Stella |
9675530 |
June 2017 |
Focht |
9717674 |
August 2017 |
Guskey |
9750674 |
September 2017 |
Wei |
9808408 |
November 2017 |
Stella |
9931282 |
April 2018 |
Restrepo et al. |
9943468 |
April 2018 |
Stevenson |
10085924 |
October 2018 |
Wei |
10588858 |
March 2020 |
Tamarkin |
2001/0006088 |
July 2001 |
Lyle |
2002/0042448 |
April 2002 |
Sorrentino et al. |
2002/0122772 |
September 2002 |
Lukenbach |
2002/0182112 |
December 2002 |
Thorn |
2003/0003069 |
January 2003 |
Carson |
2003/0083210 |
May 2003 |
Goldberg |
2003/0147842 |
August 2003 |
Restle et al. |
2003/0161852 |
August 2003 |
Miller |
2003/0171230 |
September 2003 |
Shana'a et al. |
2003/0180246 |
September 2003 |
Frantz |
2003/0207988 |
November 2003 |
Tamareselvy |
2003/0232101 |
December 2003 |
Travis |
2004/0009138 |
January 2004 |
Kling |
2004/0028932 |
February 2004 |
Holzer |
2004/0057920 |
March 2004 |
Focht |
2004/0091445 |
May 2004 |
Dykstra |
2004/0092415 |
May 2004 |
Focht et al. |
2004/0092425 |
May 2004 |
Boutique |
2004/0105827 |
June 2004 |
Grimm |
2004/0146475 |
July 2004 |
Peffly |
2004/0158940 |
August 2004 |
Wells |
2004/0180020 |
September 2004 |
Manelski |
2004/0219119 |
November 2004 |
Wei |
2004/0223929 |
November 2004 |
Clapp et al. |
2004/0223939 |
November 2004 |
Clausen |
2004/0223991 |
November 2004 |
Wei et al. |
2004/0223992 |
November 2004 |
Clapp |
2004/0232023 |
November 2004 |
Bansal |
2004/0235693 |
November 2004 |
Wei |
2004/0235702 |
November 2004 |
Hawkins |
2004/0248748 |
December 2004 |
Wei |
2004/0248749 |
December 2004 |
Mitra |
2005/0003975 |
January 2005 |
Browne |
2005/0019299 |
January 2005 |
Librizzi et al. |
2005/0020468 |
January 2005 |
Rhodia |
2005/0049172 |
March 2005 |
Lukenbach et al. |
2005/0063930 |
March 2005 |
Carlsson |
2005/0070452 |
March 2005 |
Librizzi |
2005/0075256 |
April 2005 |
Librizzi et al. |
2005/0100570 |
May 2005 |
Wei et al. |
2005/0129759 |
June 2005 |
Sojka |
2005/0139574 |
June 2005 |
Simone |
2005/0143269 |
June 2005 |
Wei |
2005/0191709 |
September 2005 |
Hendrix |
2005/0192187 |
September 2005 |
Wagner |
2005/0192188 |
September 2005 |
Wagner |
2005/0192189 |
September 2005 |
Wagner |
2005/0221334 |
October 2005 |
Benson |
2005/0238680 |
October 2005 |
Stella |
2005/0249758 |
November 2005 |
Di |
2005/0269372 |
December 2005 |
Smith |
2005/0276768 |
December 2005 |
Wei et al. |
2005/0287088 |
December 2005 |
Guiramand |
2006/0002880 |
January 2006 |
Peffly |
2006/0008438 |
January 2006 |
Velarde |
2006/0040834 |
February 2006 |
Hilliard et al. |
2006/0042184 |
March 2006 |
Perkins |
2006/0079417 |
April 2006 |
Wagner |
2006/0079419 |
April 2006 |
Wagner et al. |
2006/0079420 |
April 2006 |
Wagner et al. |
2006/0079421 |
April 2006 |
Wagner et al. |
2006/0094628 |
May 2006 |
Wei |
2006/0094635 |
May 2006 |
Pereira |
2006/0182699 |
August 2006 |
Taylor et al. |
2006/0189495 |
August 2006 |
Librizzi et al. |
2006/0193800 |
August 2006 |
Reinhardt et al. |
2006/0210505 |
September 2006 |
Clapp |
2006/0257348 |
November 2006 |
Walters |
2006/0269501 |
November 2006 |
Johnson |
2006/0276357 |
December 2006 |
Smith |
2006/0276768 |
December 2006 |
Miller |
2007/0141001 |
June 2007 |
Clapp |
2007/0155637 |
July 2007 |
Smith et al. |
2007/0187274 |
August 2007 |
Dalea |
2007/0196344 |
August 2007 |
Osborne et al. |
2007/0202488 |
August 2007 |
Hendrix |
2007/0202489 |
August 2007 |
Hendrix |
2007/0202490 |
August 2007 |
Hendrix |
2007/0202491 |
August 2007 |
Hendrix |
2007/0224154 |
September 2007 |
Brumbaugh |
2007/0224696 |
September 2007 |
Honkonen et al. |
2007/0248562 |
October 2007 |
Berry |
2007/0280976 |
December 2007 |
Taylor |
2007/0286832 |
December 2007 |
Clapp et al. |
2008/0039353 |
February 2008 |
Focht |
2008/0045428 |
February 2008 |
Focht |
2008/0045429 |
February 2008 |
Focht |
2008/0095733 |
April 2008 |
Griffin et al. |
2008/0112913 |
May 2008 |
Librizzi et al. |
2008/0196787 |
August 2008 |
Comstock |
2008/0233061 |
September 2008 |
Gates et al. |
2008/0242573 |
October 2008 |
Wei |
2009/0005449 |
January 2009 |
Gunn et al. |
2009/0005460 |
January 2009 |
Gunn et al. |
2009/0028809 |
January 2009 |
Cetti |
2009/0042765 |
February 2009 |
Gizaw |
2009/0107062 |
April 2009 |
Pedersen |
2009/0148392 |
June 2009 |
SenGupta |
2009/0162443 |
June 2009 |
Anthony |
2009/0209600 |
August 2009 |
Miner |
2009/0220443 |
September 2009 |
Braksmayer |
2009/0227751 |
September 2009 |
Yoshinaka |
2009/0311348 |
December 2009 |
Einarsson et al. |
2009/0324521 |
December 2009 |
Cetti |
2010/0022454 |
January 2010 |
Norskov-lauritsen |
2010/0022455 |
January 2010 |
Chilkoti |
2010/0022456 |
January 2010 |
Christensen |
2010/0022458 |
January 2010 |
Kopke |
2010/0028376 |
February 2010 |
Einarsson et al. |
2010/0040074 |
February 2010 |
Dropps |
2010/0040075 |
February 2010 |
Kalhoff |
2010/0048706 |
February 2010 |
Subramanyam |
2010/0105102 |
April 2010 |
Hanes |
2010/0158830 |
June 2010 |
Wei et al. |
2010/0184847 |
July 2010 |
Shin |
2010/0190675 |
July 2010 |
Cetti |
2010/0209374 |
August 2010 |
Wei |
2010/0216707 |
August 2010 |
Bernard et al. |
2010/0317677 |
December 2010 |
Hassel |
2010/0322878 |
December 2010 |
Stella et al. |
2011/0033842 |
February 2011 |
Moon |
2011/0038830 |
February 2011 |
Bernard et al. |
2011/0045037 |
February 2011 |
Tamarkin |
2011/0045039 |
February 2011 |
Sunkel |
2011/0064688 |
March 2011 |
Jordan |
2011/0071123 |
March 2011 |
Schwartz |
2011/0089196 |
April 2011 |
Cetti |
2011/0091439 |
April 2011 |
Bernard et al. |
2011/0117225 |
May 2011 |
Wei |
2011/0162668 |
July 2011 |
Coffindaffer |
2011/0165607 |
July 2011 |
Takeda |
2011/0245124 |
October 2011 |
Tsaur et al. |
2011/0245125 |
October 2011 |
Tsaur |
2011/0247954 |
October 2011 |
Wei |
2011/0250141 |
October 2011 |
Wei |
2011/0251872 |
October 2011 |
Wei |
2011/0253157 |
October 2011 |
Wei |
2011/0253158 |
October 2011 |
Wei |
2011/0257020 |
October 2011 |
Stella et al. |
2011/0257030 |
October 2011 |
Stella et al. |
2011/0262025 |
October 2011 |
Jarrold |
2011/0262570 |
October 2011 |
Finlay |
2011/0268802 |
November 2011 |
Dihora et al. |
2011/0269657 |
November 2011 |
Dihora et al. |
2011/0280822 |
November 2011 |
Griffin et al. |
2011/0281256 |
November 2011 |
Davis |
2011/0281366 |
November 2011 |
Davis |
2011/0305653 |
December 2011 |
Jordan |
2012/0009285 |
January 2012 |
Wei et al. |
2012/0010303 |
January 2012 |
Mujkic |
2012/0035557 |
February 2012 |
Coffindaffer |
2012/0087882 |
April 2012 |
Fevola |
2012/0093753 |
April 2012 |
Fevola |
2012/0184448 |
July 2012 |
Stella et al. |
2012/0197016 |
August 2012 |
Laughlin |
2012/0258074 |
October 2012 |
Mills |
2012/0258126 |
October 2012 |
Schoeller |
2012/0276175 |
November 2012 |
Dihora et al. |
2012/0276177 |
November 2012 |
Hilliard, Jr. |
2012/0276210 |
November 2012 |
Dihora et al. |
2012/0282309 |
November 2012 |
Dihora et al. |
2012/0283112 |
November 2012 |
Binder |
2012/0316095 |
December 2012 |
Wei et al. |
2013/0115610 |
May 2013 |
Lanzalaco |
2013/0115648 |
May 2013 |
Lanzalaco |
2013/0149273 |
June 2013 |
Wei et al. |
2013/0183360 |
July 2013 |
Lips et al. |
2013/0225468 |
August 2013 |
Corominas |
2013/0253057 |
September 2013 |
Wei et al. |
2013/0280174 |
October 2013 |
Lipic |
2013/0280192 |
October 2013 |
Carter et al. |
2013/0280193 |
October 2013 |
Carter |
2013/0280202 |
October 2013 |
Stella |
2013/0280356 |
October 2013 |
Stella et al. |
2013/0281551 |
October 2013 |
Stella et al. |
2013/0344012 |
December 2013 |
Cohen |
2014/0023606 |
January 2014 |
Scheunemann |
2014/0057997 |
February 2014 |
Chevalier |
2014/0072533 |
March 2014 |
Lanzalaco |
2014/0197309 |
July 2014 |
Davis |
2014/0219946 |
August 2014 |
Hloucha |
2014/0357714 |
December 2014 |
Braksmayer |
2015/0071977 |
March 2015 |
Dihora |
2015/0096582 |
April 2015 |
Stella |
2015/0098920 |
April 2015 |
Stella |
2016/0122806 |
May 2016 |
Amini |
2016/0128913 |
May 2016 |
Wei et al. |
2016/0128917 |
May 2016 |
Wei |
2016/0128927 |
May 2016 |
Wei et al. |
2016/0128930 |
May 2016 |
Stella et al. |
2016/0129917 |
May 2016 |
Gariepy |
2016/0310375 |
October 2016 |
Torres Rivera |
2017/0000711 |
January 2017 |
Jansen |
2017/0049673 |
February 2017 |
Wei |
2017/0165155 |
June 2017 |
Glenn, Jr. |
2017/0165164 |
June 2017 |
Zhao et al. |
2017/0228514 |
August 2017 |
Apte |
2017/0333315 |
November 2017 |
Wei |
2018/0055894 |
March 2018 |
Kim |
2018/0110704 |
April 2018 |
Zhao |
2018/0185255 |
July 2018 |
Wei |
2018/0353394 |
December 2018 |
Skubsch |
2018/0360706 |
December 2018 |
Dihora |
2019/0117537 |
April 2019 |
Wei |
2019/0117546 |
April 2019 |
Wei |
2019/0142714 |
May 2019 |
Dihora |
2019/0178774 |
June 2019 |
Wei |
2020/0040373 |
February 2020 |
Wei |
2020/0146967 |
May 2020 |
Wei |
|
Foreign Patent Documents
|
|
|
|
|
|
|
110804666 |
|
Feb 2020 |
|
CN |
|
20122018 |
|
Dec 2003 |
|
DE |
|
10 2008 035 172 |
|
Feb 2010 |
|
DE |
|
0078138 |
|
May 1983 |
|
EP |
|
0937495 |
|
Aug 1999 |
|
EP |
|
1005849 |
|
Sep 2001 |
|
EP |
|
1064918 |
|
Sep 2002 |
|
EP |
|
1243321 |
|
Sep 2002 |
|
EP |
|
0907345 |
|
May 2003 |
|
EP |
|
1657159 |
|
Aug 2007 |
|
EP |
|
1 383 542 |
|
Apr 2008 |
|
EP |
|
2505180 |
|
Oct 2012 |
|
EP |
|
2233036 |
|
Jan 1975 |
|
FR |
|
2792728 |
|
Oct 2000 |
|
FR |
|
2 924 947 |
|
Mar 2010 |
|
FR |
|
2 925 314 |
|
Nov 2012 |
|
FR |
|
2 908 784 |
|
Dec 2012 |
|
FR |
|
2 924 613 |
|
Dec 2012 |
|
FR |
|
2 924 614 |
|
Dec 2012 |
|
FR |
|
2245585 |
|
Aug 1992 |
|
GB |
|
2431345 |
|
May 2009 |
|
GB |
|
S 61155311 |
|
Jul 1986 |
|
JP |
|
03095110 |
|
Apr 1991 |
|
JP |
|
04149112 |
|
May 1992 |
|
JP |
|
6262060 |
|
Sep 1994 |
|
JP |
|
8220550 |
|
Aug 1996 |
|
JP |
|
10216106 |
|
Aug 1998 |
|
JP |
|
2000229817 |
|
Aug 2000 |
|
JP |
|
2002128639 |
|
May 2002 |
|
JP |
|
2002138010 |
|
May 2002 |
|
JP |
|
2009084224 |
|
Apr 2009 |
|
JP |
|
2009126791 |
|
Jun 2009 |
|
JP |
|
2010235567 |
|
Oct 2010 |
|
JP |
|
2011178667 |
|
Sep 2011 |
|
JP |
|
1020110068049 |
|
Jun 2011 |
|
KR |
|
1020120009774 |
|
Feb 2012 |
|
KR |
|
20170102857 |
|
Sep 2017 |
|
KR |
|
9212911 |
|
Aug 1992 |
|
WO |
|
9401084 |
|
Jan 1994 |
|
WO |
|
9410973 |
|
May 1994 |
|
WO |
|
WO 95/34280 |
|
Dec 1995 |
|
WO |
|
9602225 |
|
Feb 1996 |
|
WO |
|
9629979 |
|
Oct 1996 |
|
WO |
|
9717938 |
|
May 1997 |
|
WO |
|
9827193 |
|
Jun 1998 |
|
WO |
|
9938491 |
|
Aug 1999 |
|
WO |
|
9946319 |
|
Sep 1999 |
|
WO |
|
0030597 |
|
Jun 2000 |
|
WO |
|
0066612 |
|
Nov 2000 |
|
WO |
|
0067712 |
|
Nov 2000 |
|
WO |
|
0075240 |
|
Dec 2000 |
|
WO |
|
0101931 |
|
Jan 2001 |
|
WO |
|
0155497 |
|
Aug 2001 |
|
WO |
|
02100358 |
|
Dec 2002 |
|
WO |
|
03105796 |
|
Dec 2003 |
|
WO |
|
2006113117 |
|
Oct 2006 |
|
WO |
|
2007129330 |
|
Nov 2007 |
|
WO |
|
2007129331 |
|
Nov 2007 |
|
WO |
|
2008074624 |
|
Jun 2008 |
|
WO |
|
2009001260 |
|
Dec 2008 |
|
WO |
|
WO2008148672 |
|
Dec 2008 |
|
WO |
|
2009077995 |
|
Jun 2009 |
|
WO |
|
2009081374 |
|
Jul 2009 |
|
WO |
|
WO 2009/081368 |
|
Jul 2009 |
|
WO |
|
WO 2010/079468 |
|
Jul 2010 |
|
WO |
|
2011133538 |
|
Oct 2011 |
|
WO |
|
WO 2012/138710 |
|
Oct 2012 |
|
WO |
|
2015044315 |
|
Apr 2015 |
|
WO |
|
Other References
US. Appl. No. 61/657,145, filed Jun. 8, 2012, Karl Shiqing Wei et
al. cited by applicant .
U.S. Appl. No. 16/943,888, filed Jul. 30, 2020, Wei et al. cited by
applicant .
U.S. Appl. No. 17/108,560, filed Dec. 2, 2020, Wei et al. cited by
applicant .
International Search Report PCT/US2015/059926 including the Written
Opinion of the International Searching Authority, dated Jan. 8,
2016, 12 pages. cited by applicant .
"Composition and Applications of Aloe Vera Leaf Gel", Josias H.
Hamman, Published Aug. 8, 2008, Molecules 2008, 13, 1599-1616.
cited by applicant .
All final and non-final office actions for U.S. Appl. No.
12/054,853. cited by applicant .
All final and non-final office actions for U.S. Appl. No.
12/814,307. cited by applicant .
All final and non-final office actions for U.S. Appl. No.
13/007,630. cited by applicant .
All final and non-final office actions for U.S. Appl. No.
13/007,631. cited by applicant .
All final and non-final office actions for U.S. Appl. No.
13/007,632. cited by applicant .
All final and non-final office actions for U.S. Appl. No.
13/157,665. cited by applicant .
All final and non-final office actions for U.S. Appl. No.
13/491,634. cited by applicant .
All final and non-final office actions for U.S. Appl. No.
13/707,108. cited by applicant .
All final and non-final office actions for U.S. Appl. No.
13/848,271. cited by applicant .
All final and non-final office actions for U.S. Appl. No.
13/865,554. cited by applicant .
All final and non-final office actions for U.S. Appl. No.
13/865,588. cited by applicant .
All final and non-final office actions for U.S. Appl. No.
14/937,089. cited by applicant .
All final and non-final office actions for U.S. Appl. No.
14/937,171. cited by applicant .
All final and non-final office actions for U.S. Appl. No.
14/937,335. cited by applicant .
All final and non-final office actions for U.S. Appl. No.
14/937,425. cited by applicant .
All final and non-final office actions for U.S. Appl. No.
15/669,001. cited by applicant .
All final and non-final office actions for U.S. Appl. No.
15/859,925. cited by applicant .
All final and non-final office actions for U.S. Appl. No.
16/055,604. cited by applicant .
All final and non-final office actions for U.S. Appl. No.
16/165,086. cited by applicant .
All final and non-final office actions for U.S. Appl. No.
16/165,146. cited by applicant .
All final and non-final office actions for U.S. Appl. No.
16/211,531. cited by applicant .
All final and non-final office actions for U.S. Appl. No.
16/270,861. cited by applicant .
All final and non-final office actions for U.S. Appl. No.
16/697,946. cited by applicant .
All final and non-final office actions for U.S. Appl. No.
16/740,573. cited by applicant .
All final and non-final office actions for U.S. Appl. No.
16/943,888. cited by applicant .
All final and non-final office actions for U.S. Appl. No.
17/108,560. cited by applicant .
All final and non-final office actions for U.S. Appl. No.
29/389,585. cited by applicant .
All final and non-final office actions for U.S. Appl. No.
29/438,169. cited by applicant .
Becker et al., Detection of Differentially Regulated Genes in
Keratinocytes by cDNA Array Hybridization: Hsp27 and Other Novel
Players in Response to Artificial Ultraviolet Radiation, Journal of
Investigative Dermatology, vol. 116, No. 6, Jun. 2001, pp. 983-988.
cited by applicant .
Clariant "Mild Surfactants Clariant Mild Surfactants for Personal
Care Applications" Jul. 23, 2015. cited by applicant .
Cocamidopropyl betaine Product Specification, Edition 1, Jun. 2005.
cited by applicant .
Conti et al., Seasonal influences on stratum corneum ceramide 1
fatty acids and the influence of topical essential fatty acids,
International Journal of Cosmetic Science 18, 1-12 (1996). cited by
applicant .
D.J. Burgess, Practical Analysis of Complex Coacervate Systems,
Journal of Colloid and Interface Science, vol. 140, No. 1, Nov.
1990, pp. 227-238. cited by applicant .
Erhirhie et al. Medicinal Values of Citrullus lanatus (Watermelon):
Pharmacological Review. International Journal of Research in
Pharmaceutical and Biomedical Sciences 2013, vol. 4, No. 4, pp.
1305-1312 (Year: 2013). cited by applicant .
Ertel et al., Leg wash protocol to assess the skin moisturization
potential of personal cleansing products, International Journal of
Cosmetic Science, vol. 21, No. 6 Dec. 1999, pp. 383-397. cited by
applicant .
FDA CFR 21 201.57 (Apr. 1, 2008 edition). cited by applicant .
Flores et al. Microbiome of Affected and Unaffected Skin of
Patients with Atopic Dermatitis Before and After Emollient
Treatment Journal of Drugs in Dermatology 2014, vol. 13, issue 11,
pp. 611-618 (Year: 2014). cited by applicant .
Grando et al., Adrenergic and Cholinergic Control in the Biology of
Epidermis: Physiological and Clinical Significance, Journal of
Investigative Dermatology vol. 126, pp. 1948-1965 (2006). cited by
applicant .
Grice and Segre. The skin microbiome. Nature Reviews Microbiology
2011, vol. 9, pp. 244-253 (Year: 2011). cited by applicant .
Household Products Database, Brand Information, "Olay Daily Renewal
Moisturizing Body Wash, Calming," [Online] URL:
http://householdproducts.nlm.nih.gov/cgi-bin/household/brands?tbl=brands&-
id=16003084, accessed Feb. 8, 2006 (2 pages). cited by applicant
.
International Search Report and Written Opinion of the
International Searching Authority PCT/US2010/040074 dated Jan. 21,
2011, 18 pages. cited by applicant .
International Search Report and Written Opinion of the
International Searching Authority PCT/US2010/040075 dated Dec. 1,
2010, 22 pages. cited by applicant .
International Search Report and Written Opinion of the
International Searching Authority PCT/US2010/040077 dated Nov. 30,
2010, 18 pages. cited by applicant .
International Search Report and Written Opinion of the
International Searching Authority, PCT/US2011/039907, dated Feb.
16, 2012, 13 pages. cited by applicant .
International Search Report and Written Opinion of the
International Searching Authority, PCT/US2012/068227, dated Jun.
11, 2014, 12 pages. cited by applicant .
International Search Report and Written Opinion of the
International Searching Authority, PCT/US2013/037164, dated Sep. 6,
2013, 9 pages. cited by applicant .
International Search Report and Written Opinion of the
International Searching Authority, PCT/US2015/059922, dated Jan. 8,
2016, 14 pages. cited by applicant .
International Search Report and Written Opinion of the
International Searching Authority, PCT/US2018/012287, dated Apr.
13, 2018, 15 pages. cited by applicant .
International Search Report and Written Opinion of the
International Searching Authority, PCT/US2018/056228, dated Feb.
12, 2019, 14 pages. cited by applicant .
International Search Report and Written Opinion of the
International Searching Authority, PCT/US2018/056232, dated Mar. 6,
2019, 13 pages. cited by applicant .
International Search Report and Written Opinion of the
International Searching Authority, PCT/US2019/044778, dated Oct.
25, 2019, 13 pages. cited by applicant .
J. Caelles et al., Anionic and Cationic Compounds in Mixed Systems,
Cosmetics & Toiletries, vol. 106, Apr. 1991, pp. 49-54. cited
by applicant .
J. Crank, The Mathematics of Diffusion, 2nd Edition, 1975, p. 63.
cited by applicant .
Jing, G. et al., Parallel-META 3: Compreshensive taxonomical and
functional analysis platform for efficient comparison of microbial
communities, Scientific Reports, 7:40371, DOI: 10.1038/srep40371
(2017), 11 pages. cited by applicant .
Jun. 2009 (Jun. 2009). "Tahitian Escape Exfoliating Body Wash",
XP0Q2752393, Database accession No. 1124626. cited by applicant
.
Kikuchi et al., Improvement of Mild Inflammatory Changes of the
Facial Skin Induced by Winter Environment with Daily Applications
of a Moisturizing Cream. AHalf-Side Test of Biophysical Skin
Parameters, Cytokine Expression Pattern and the Formation of
Cornified Envelope, Dermatology, vol. 207, No. 3, 2003, pp.
269-275. cited by applicant .
KOBO Brochure, Treated Pigments, May 2000. cited by applicant .
Kong et al. Performing Skin Microbiome Research: A Method to the
Madness. Journal of Investigative Dermatology 2016, vol. 137, pp.
561-568 (Year: 2016). cited by applicant .
Kong, et al., Temporal shifts in the skin microbiome associated
with disease flares and treatment in children with atopic
dermatitis, Genome Research, 2012, 22:850-859, Published by Cold
Spring Harbor Laboratory Press. cited by applicant .
Mar. 2011 (Mar. 2011), "Healthy Shower Gel", XP002752392. Database
accession No. 1513292. cited by applicant .
Marzatico et al., Evaluation of anti-wrinkle, elasticizing,
ridensifying and skin barrier "repairing" efficacy of a cosmetic
treatment, Farcoderm Tested Wellness, BIOTIVIA, Jun. 18, 2009, 42
pages. cited by applicant .
Meisel et al. Skin Microbiome Surveys are strongly influenced by
experimental design. Journal of Investigative Dermatology 2016,
vol. 136, pp. 947-946 (Year: 2016). cited by applicant .
Michael Starch: "New Cosmetic Ingredients Based on Soybean Oil",
IP.com journal, IP.com Inc., West Henrietta NY, US, Jun. 15, 2007,
pp. 6, 12, 14. cited by applicant .
Milton, Section 9.2: Testing Hypotheses on a Proportion,
Introduction to Probability and Statistics, Fourth Edition, Sep.
30, 2002, pp. 129-131. cited by applicant .
Niemeyer et al. A systematic literature review of the human skin
microbiome as biomarker for dermatological drug development.
British Journal of Clinical Pharmacology 2018, vol. 84, pp.
2178-2193 (Year: 2018). cited by applicant .
Nov. 2013 (Nov. 2013), "Shampoo", XPO02752391, Database accession
No. 2242340. cited by applicant .
PCT International Search Report and Written Opinion for
PCT/US2008/058556 dated Oct. 22, 2010. cited by applicant .
PCT International Search Report and Written Opinion for
PCT/US2011/057608 dated Apr. 27, 2012. cited by applicant .
PCT International Search Report and Written Opinion for
PCT/US2013/033275 dated Mar. 7, 2014. cited by applicant .
PCT International Search Report and Written Opinion for
PCT/US2013/037165 dated Sep. 12, 2013. cited by applicant .
PCT International Search Report and Written Opinion for
PCT/US2015/059684; dated Jan. 11, 2016. cited by applicant .
Raja K Sivamani et al: "An Epinephrine-Dependent Mechanism for
theControl of UV-Induced Pigmentation", Journal of Investigative
Dermatology, vol. 129, No. 3, Aug. 21, 2008 (Aug. 21, 2008), pp.
784-787. cited by applicant .
Rogers et al., Stratum corneum lipids: the effect of ageing and the
seasons, Archives of Dermatological Research (1996), 288 : 765-770.
cited by applicant .
Schallreuter et al., The induction of the .alpha.-1-adrenoreceptor
signal transduction system on human melanocytes, Experimental
Dermatology 1996; vol. 5, Issue 1, pp. 20-23. cited by applicant
.
Seite et al., Barrier function and microbiotic dysbiosis in atopic
dermatitis, Clinical, Cosmetic and Investigational Dermatology,
vol. 8, 2015, pp. 479-483. cited by applicant .
Sep. 2014 (Sep. 2014)"Extra Mild Moisturising Bar", XP002752390,
Database accession No. 2527423. cited by applicant .
Sun et al., A Microbiome-Based Index for Assessing Skin Health and
Treatment Effects for Atopic Dermatitis in Children, mSystems, vol.
4, Issue 4, e00293-19, Jul./Aug. 2019. cited by applicant .
Tate Owen, Roger Pynn, Jennifer S. Martinez, and Alison Butler;
Micelle-to-Vesicle Transition of an Iron-Chelating Microbial
Surfactant, Marinobactin E; Nov. 12, 2005; Langmuir, 21,26,
12109-12114 (Year: 2005). cited by applicant .
Triethanolamine Product Specification, Chemical Book, 2008. cited
by applicant .
Two et al. The Cutaneous Microbiome and Aspects of Skin
Antimicrobial Defense System Resist Acute Treatment with Topical
Skin Cleansers. Journal of Investigative Dermatology 2016, vol.
136, pp. 1950-1954 (Year: 2016). cited by applicant .
Van Oss, C.J., Coacervation, Complex Coacervation and Flocculation,
Journal of Dispersion Science, vol. 9, 1989. cited by applicant
.
Vaughan, C. D., Solubility, Effects in Product, Package,
Penetration and Preservation, Cosmetics and Toiletries, vol. 103,
Oct. 1988. cited by applicant .
Voegeli et al., Efficient and simple quantification of stratum
corneum proteins on tape strippings by infrared densitometry, Skin
Research and Technology 2007; 13; 242-251. cited by applicant .
XP 002332778 "Dove All Day Moisturizing Body Wash" Online URL:
http://www.ewg.org/reports/skindeep2/report.php?type=PRODUCT&id=8801874.
cited by applicant .
Xu et al., Skin benfits of moisturising body wash formulas for
children with atopic dermatitis: A randomised controlled clinical
study in China, Australasian Journal of Dermatology (2019). cited
by applicant .
Yogiraj et al. Garica papaya Linn: An overview. International
Journal of Herbal Medicine 2014, vol. 2, No. 5, pp. 01-08 (Year:
2014). cited by applicant .
"Effects of xerosis and aging on epidermal proliferation and
differentiation", Br. J. Dermatology, 137: 219-225 (1997) M.
Engelke. cited by applicant .
"The validity and practicality of sun-reactive skin types I through
VI". Arch. Dermatology, 124: 869-871 (1988). cited by
applicant.
|
Primary Examiner: Ogden, Jr.; Necholus
Attorney, Agent or Firm: Haughey; Angela K.
Claims
What is claimed is:
1. A personal care composition containing a microcapsule consisting
of: a structured cleansing phase comprising about 2% to about 50%
of an anionic surfactant; a benefit phase comprising at least one
triglyceride oil selected from the group consisting of olive oil,
sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil,
palm oil, coconut oil, palm kernel oil, and mixtures thereof at a
level that does not impair the formation of the clusters of
microcapsules upon dilution of said composition with water; from
about 0.01% to about 2% of a first and second cationic deposition
polymer; a plurality of anionic microcapsules wherein the Zeta
potential of said microcapsules is less than negative 0.5
millivolts and the weight ratio of said microcapsules to cationic
polymers is from about 5:1 to about 12:1; a carrier and wherein the
personal care composition optionally contains a dye, preservative,
perfume and mixtures thereof.
2. The personal care composition of claim 1, wherein said cationic
deposition polymer and said plurality of anionic microcapsules are
added to the personal cleansing composition as a premix.
3. The personal care composition of claim 1, wherein the structured
cleansing phase and the benefit phase are in physical contact with
each other.
4. The personal care composition of claim 1, wherein the anionic
surfactant is selected from the group consisting of ammonium lauryl
sulfate, ammonium laureth sulfate, sodium lauryl sulfate, sodium
laureth sulfate, potassium laureth sulfate, sodium lauryl
sarcosinate, sodium lauroyl sarcosinate, lauryl sarcosine, cocoyl
sarcosine, ammonium cocoyl sulfate, potassium lauryl sulfate, and
combinations thereof.
5. The personal care composition of claim 1, wherein the cationic
deposition polymer is selected from the group consisting of
starches, guar, cellulose, Cassia, locust bean, Konjac, Tara,
galactomannan, and tapioca.
6. The personal care composition of claim 1, wherein the anionic
surfactant comprises sodium laureth(n) sulfate.
7. The personal care composition of claim 1, wherein the
microcapsules comprise a core material and a wall material, the
wall material selected from the group consisting of those formed
from melamine-formaldehyde or urea-formaldehyde condensates,
melamine-resorcinol or urea-resorcinol condensates, aminoplasts,
gelatin, polyurethane, polyamide, polyolefin, polysaccharide,
protein, silicone, lipid, modified cellulose, gums, polyacrylate,
polyphosphate, polystyrene, and polyesters, or combinations
thereof.
8. A personal care composition consisting of: a structured
cleansing phase comprising 2% to 30%, by weight of the composition,
of an anionic surfactant; a benefit phase comprising at least one
triglyceride oil selected from the group consisting of olive oil,
sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil,
palm oil, coconut oil, palm kernel oil, and mixtures thereof at a
level that does not impair the formation of the clusters of
microcapsules upon dilution of said composition with water; from
0.05% to 5%, by weight of the composition, of a microcapsule premix
comprising a first cationic deposition polymer and anionic
microcapsules wherein the Zeta potential of said microcapsules is
less than negative 0.5 millivolts and the weight ratio of said
microcapsules to cationic polymer is from about 5:1 to about 12:1;
a carrier and wherein the personal care composition optionally
contains a dye, preservative, perfume and mixtures thereof.
9. The personal care composition of claim 8, wherein the first
cationic deposition polymer has a molecular weight of 300,000 Da to
2,000,000 Da.
10. The personal care composition of claim 9, wherein the first
cationic deposition polymer comprises polyvinyl formamide.
11. The personal care composition of claim 10, wherein the anionic
microcapsules comprise a shell comprising polyacrylate, melamine
formaldehyde, or a combination thereof.
12. The personal care composition of claim 11, wherein the anionic
microcapsules comprise a core comprising perfume.
13. The personal care composition of claim 8, wherein the blending
ratio of the structured cleansing phase to the benefit phase is
50:50.
Description
TECHNICAL FIELD
The present disclosure relates to personal care compositions that
include microcapsules and triglycerides; and methods relating
thereto.
BACKGROUND
Cleansing the skin is an activity that has been done for millennia.
Skin cleansing and methods therefore have involved the utilization
of soaps, body washes, and other personal care compositions.
Personal care compositions can be structured to suspend and
stabilize dispersions of benefit agents while maintaining physical
integrity of the compositions, and there are many ways to provide
such structure. The ability to provide structure can be an
important property for such compositions, but it is also important
for personal care compositions to have the ability to rapidly
become micellar upon dilution to clean the skin and to deposit
benefit agents. Having too much structure in a composition can
result in poor performance, but not having enough structure in a
composition can cause the product to be unstable. Further,
achieving a balance between these two properties can be a difficult
task. Furthermore, such personal care compositions also often
include fragrances. Such fragrances may delight the user by
providing a freshness feeling and may serve as a signal to the user
that the product may still be working or that the product is still
present. Yet because of the volatility of many fragrances and/or
habituation, a consumer may be unable to notice the fragrance
shortly after using/applying the personal care composition.
Consequentially, it may be desirable to have technologies than
improve the noticeability of fragrances in personal care
compositions while also providing structure to the personal care
composition.
SUMMARY
A personal care composition comprising a structured cleansing phase
comprising about 2% to about 50% of an anionic surfactant and a
benefit phase comprising triglycerides; from about 0.01% to about
2% of a cationic deposition polymer; a plurality of anionic
microcapsules; and a carrier.
A method of making a personal cleansing composition, the method
comprising adding a premix, said premix comprising a plurality of
anionic microcapsules and a cationic deposition polymer to a
mixture comprising a structured cleansing phase comprising about 2%
to about 50% of an anionic surfactant, a benefit phase comprising
triglycerides, and a carrier to form a personal care
composition.
BRIEF DESCRIPTION OF THE DRAWINGS
While the specification concludes with claims, it is believed that
the same will be better understood from the following description
taken in conjunction with the accompanying drawings in which:
FIG. 1 is an image showing a dilution of 1 part of a personal care
composition including 7% by weight of the composition of soybean
oil to 9 parts of water;
FIG. 2 is an image showing a dilution of 1 part of a personal care
composition including 7% by weight of the composition of soybean
oil and 0.2% by weight of the composition of non-ionic
microcapsules (having a core material including a perfume oil and a
polyacrylate wall material) to 9 parts of water that results in a
lack of clusters of microcapsules;
FIG. 3 is an image showing a dilution of 1 part of a personal care
composition including 7% by weight of the composition of soybean
oil and 0.2% by weight of the composition of cationic microcapsules
(having a core material including a perfume oil and a polyacrylate
wall material) to 9 parts of water that results in a lack of
clusters of microcapsules;
FIG. 4 is an image showing a dilution of 1 part of a personal care
composition including 7% by weight of the composition of soybean
oil and 0.2% by weight of the composition of anionic microcapsules
(having a core material including a perfume oil and a polyacrylate
wall material) to 9 parts of water that results in the formation of
clusters of microcapsules;
FIG. 5 is an image showing a dilution of 1 part of a personal care
composition including 7% by weight of the composition of soybean
oil and 0.2% by weight of the composition of anionic microcapsules
(having a core material including a perfume oil and a wall material
made from melamine-formaldehyde condensates) to 9 parts of water
that results in the formation clusters of microcapsules; and
FIG. 6 is an image showing a dilution of 1 part of a personal care
composition including 7% by weight of the composition of soybean
oil and 0.2% by weight of the composition of anionic microcapsules
(having a core material including a perfume oil that is different
from the microcapsules used in FIG. 5 and a wall material made from
melamine-formaldehyde condensates) to 9 parts of water that results
in the formation of clusters of microcapsules.
DETAILED DESCRIPTION
While the specification concludes with the claims particularly
pointing and distinctly claiming the invention, it is believed that
the present invention will be better understood from the following
description.
The devices, apparatuses, methods, components, and/or compositions
of the present invention can include, consist essentially of, or
consist of, the components of the present invention as well as
other ingredients described herein. As used herein, "consisting
essentially of" means that the devices, apparatuses, methods,
components, and/or compositions may include additional ingredients,
but only if the additional ingredients do not materially alter the
basic and novel characteristics of the claimed devices,
apparatuses, methods, components, and/or compositions.
All percentages and ratios used herein are by weight of the total
composition and all measurements made are at 25.degree. C., unless
otherwise designated.
All measurements used herein are in metric units unless otherwise
specified.
I. DEFINITIONS
As used herein, the following terms shall have the meaning
specified thereafter:
"Anhydrous" refers to those compositions, and components thereof,
which are substantially free of water.
"Anionic microcapsules" refer to microcapsules with a zeta
potential of less than negative 0.5 millivolts as determined by the
method described herein.
"Associative polymer" refers to a water-dispersible polymer
comprising hydrophobic groups at an end or pendants to a
hydrophilic backbone.
"Molecular weight" as used herein with respect to polymers refers
to the weight average molecular weight unless otherwise
specified.
"Multiphase" refers to compositions comprising at least two phases
which can be chemically distinct (e.g., a structured cleansing
phase and a benefit phase). Such phases can be in direct physical
contact with one another. A personal care composition can be a
multiphase personal care composition where phases of the personal
care composition can be blended or mixed to a significant degree,
but still be physically distinct. In these situations, the physical
distinctiveness is undetectable to the naked eye. The personal care
composition can also be a multiphase personal care composition
where phases of the personal care composition can be made to occupy
separate but distinct physical spaces inside a package in which the
phases can be stored. In such an arrangement, the phases can be
stored such that they are not in direct contact with one another
(i.e., the phases are not separated by a barrier and the phases are
not emulsified or mixed to any significant degree). The personal
care composition can also be a multiphase personal care composition
where the phases are in physical contact and are visually distinct.
Visually distinct phases can take many forms (e.g., phases can
appear as striped, marbled). The personal care composition can also
include a combination of one or more of the above multiphase
personal care compositions. In one such an arrangement, one blended
multiphase personal care composition can be stacked with another
blended multiphase personal care composition to form a striped
configuration. Additionally, blended multiphase personal care
compositions distinguishable by color can be stacked as stripes
wherein the blended multiphase personal care compositions can be
otherwise similar in average composition.
"Non-associative polymer" refers to a water-dispersible polymer
with a relatively uniform hydrophilic backbone lacking hydrophobic
groups.
"Package" refers to any suitable container for a personal care
composition including but not limited to a bottle, tottle, tube,
jar, non-aerosol pump, and combinations thereof.
"Personal care composition" refers to compositions intended for
topical application to skin or hair. Personal care compositions can
be rinse-off formulations, in which the product can be applied
topically to the skin or hair and then subsequently rinsed within
seconds to minutes from the skin or hair with water. The product
could also be wiped off using a substrate. In either case, it is
believed at least a portion of the product is left behind (i.e.,
deposited) on the skin. The personal care compositions can also be
used as shaving aids. The personal care compositions can be
extrudable or dispensable from a package. The personal care
compositions can exhibit a viscosity of from about 1,500 cP to
about 1,000,000 cP as measured by a viscosity method as described
in the commonly owned, patent application published on Nov. 11,
2004 under U.S. Publication No. 2004/0223991 A1 entitled,
"Multiphase Personal Care Compositions" filed on May 7, 2004 by
Wei, et al. The personal care compositions can be in the form of,
for example, a liquid, semi-liquid cream, lotion, or gel and are
intended for topical application to the skin and/or hair. Examples
of personal care compositions can include but are not limited to
bar soap, shampoo, conditioning shampoo, body wash, moisturizing
body wash, shower gels, skin cleansers, cleansing milks, hair and
body wash, in shower body moisturizer, pet shampoo, shaving
preparations, and cleansing compositions used in conjunction with a
disposable cleansing cloth.
The term "premix" when used with respect to microcapsules refers to
a mixture that is formed by combining a plurality of anionic
microcapsules with a cationic deposition polymer.
"STnS" refers to sodium trideceth(n) sulfate, wherein n can define
the average number of moles of ethoxylate per molecule.
"Stable" refers to a personal care composition having a viscosity
change of about 30% or less from an initial viscosity value after
being rapidly aged for 10 days at 50.degree. C.
"Structured" refers to having a rheology that can confer stability
on the personal care composition. A degree of structure can be
determined by characteristics determined by a Zero Shear Viscosity
Method described below. Accordingly, a structured cleansing phase
of the personal care composition can be considered to be structured
if the structured cleansing phase has a Zero Shear Viscosity of
about 20 Pascal-seconds (Pa-s) or more, about 200 Pa-s or more,
about 500 Pa-s or more, about 1,000 Pa-s or more, about 1,500 Pa-s
or more, or about 2,000 Pa-s or more. Other methods for determining
characteristics which can define a degree of structure are
described in U.S. Patent Application Publication No.
2012/0009285.
The phrase "substantially free of" as used herein, unless otherwise
specified means that the personal care composition comprises less
than about 5%, less than about 3%, less than about 1%, or even less
than about 0.1% of the stated ingredient. The term "free of" as
used herein means that the personal care composition comprises 0%
of the stated ingredient that is the ingredient has not been added
to the personal care composition. However, these ingredients may
incidentally form as a by-product or a reaction product of the
other components of the personal care composition.
"Surfactant component" refers to a total of all anionic, nonionic,
amphoteric, zwitterionic, and cationic surfactants in a phase. When
calculations are based on the surfactant component, water and
electrolytes can be excluded from the calculations involving the
surfactant component since surfactants as manufactured can be
diluted and neutralized.
"Visually distinct" generally refers to a region of the multiphase
personal care composition having one average composition, as
distinct from another region having a different average
composition, wherein the regions can be visible to the unaided
naked eye. This would not preclude distinct regions from comprising
two similar multiphase personal care compositions or phases where
one multiphase personal care composition or phase can comprise
certain pigments, dyes, particles, and various optional
ingredients, hence providing a region of different average
composition (e.g., different textures or different colors).
II. PERSONAL CARE COMPOSITIONS
It has been surprisingly found that the development of clusters of
microcapsules is important for the deposition of microcapsules
delivered to a situs via a personal cleansing composition. In this
regard, the formation of clusters of microcapsules upon dilution of
the personal cleansing composition containing microcapsules may
improve the deposition of the microcapsules, and thereby lead to a
more noticeable bloom from the microcapsules. It has been found
that the formation of clusters of microcapsules may be initiated by
combining anionic microcapsules (microcapsules with a zeta
potential of less than negative 0.5 millivolts) with a cationic
deposition polymer to form a premix. It has also surprisingly been
found that the choice of benefit agent may influence the
development of clusters. In this regard, it has been surprisingly
found that the presence of a benefit agent comprising triglycerides
may also increase the development of clusters, and thereby leading
to an improvement in the performance of the microcapsules
A. Structured Cleansing Phase
As noted herein, a personal care composition can include a
structured cleansing phase and a benefit phase. The structured
cleansing phase and the benefit phase can be in physical contact.
The phases can be blended or mixed to a significant degree, but
still be physically distinct such that the physical distinctiveness
is undetectable to the naked eye. The phases can also be made to
occupy separate but distinct physical spaces inside a package in
which the phases are stored. In such an arrangement, the structured
cleansing phase and the benefit phase can be stored such that the
phases are not in direct contact with one another. The phases can
also be in physical contact where the phases are visibly distinct
which, for example, can give a striped or marbled
configuration.
The personal care composition can include a combination of one or
more of the above multiphase personal care compositions. For
example, one blended multiphase personal care composition can be
stacked as stripes with another blended multiphase personal care
composition.
The personal care composition of the present invention includes a
cleansing phase. The cleansing phase will comprise as least one
anionic surfactant. The surfactant may be present from about 3% to
about 20%, by weight of the personal care composition. The
cleansing phase may contain from 3% to about 20%, from about 5% to
about 15%, from about from about 7% to about 15%, from about 5% to
about 13%, or any combination of the upper, lower, and included
limits within the ranges.
The cleansing phase may be structured. When structured, the
cleansing phase is comprised of a structured domain. The structured
domain is preferably an opaque structured domain, which is
preferably a lamellar phase. The lamellar phase can provide
resistance to shear, adequate yield to suspend particles and
droplets and at the same time providing long term stability, since
it is thermodynamically stable. The lamellar phase tends to have a
viscosity that minimizes the need for viscosity modifiers, but they
can be included if desired.
Anionic surfactants can be either linear or branched. Examples of
some suitable linear anionic surfactants include ammonium laureth
sulfate, triethylamine lauryl sulfate, triethylamine laureth
sulfate, triethanolamine lauryl sulfate, triethanolamine laureth
sulfate, monoethanolamine lauryl sulfate, monoethanolamine laureth
sulfate, diethanolamine lauryl sulfate, diethanolamine laureth
sulfate, lauric monoglyceride sodium sulfate, sodium laureth
sulfate, potassium laureth sulfate, sodium lauryl sarcosinate,
sodium lauroyl sarcosinate, lauryl sarcosine, cocoyl sarcosine,
ammonium cocoyl sulfate, sodium cocoyl isethionate, ammonium
lauroyl sulfate, sodium cocoyl sulfate, sodium lauroyl sulfate,
potassium cocoyl sulfate, potassium lauryl sulfate,
monoethanolamine cocoyl sulfate, sodium tridecyl benzene sulfonate,
sodium dodecyl benzene sulfonate, and combinations thereof.
Examples of some suitable branched anionic surfactants include but
are not limited to the following surfactants: sodium trideceth
sulfate, sodium tridecyl sulfate, sodium C.sub.12-13 alkyl sulfate,
sodium C.sub.12-15 alkyl sulfate, sodium C.sub.11-15 alkyl sulfate,
sodium C.sub.12-18 alkyl sulfate, sodium C.sub.10-16 alkyl sulfate,
sodium C.sub.12-13 pareth sulfate, sodium C.sub.12-13 pareth-n
sulfate, sodium C.sub.12-14 pareth-n sulfate, and combinations
thereof. Other salts of all the aforementioned surfactants are
useful, such as TEA, DEA, ammonia, potassium salts. Useful
alkoxylates include the ethylene oxide, propylene oxide and EO/PO
mixed alkoxylates. Phosphates, carboxylates and sulfonates prepared
from branched alcohols are also useful anionic branched
surfactants. Branched surfactants can be derived from synthetic
alcohols such as the primary alcohols from the liquid hydrocarbons
produced by Fischer-Tropsch condensed syngas, for example Safol.TM.
23 Alcohol available from Sasol North America, Houston, Tex.; from
synthetic alcohols such as Neodol.TM. 23 Alcohol available from
Shell Chemicals, USA; from synthetically made alcohols such as
those described in U.S. Pat. No. 6,335,312 issued to Coffindaffer,
et al on Jan. 1, 2002. Preferred alcohols are Safol.TM. 23 and
Neodol.TM. 23. Preferred alkoxylated alcohols are Safol.TM. 23-3
and Neodol.TM. 23-3. Sulfates can be prepared by conventional
processes to high purity from a sulfur based SO.sub.3 air stream
process, chlorosulfonic acid process, sulfuric acid process, or
Oleum process. Preparation via SO.sub.3 air stream in a falling
film reactor is a preferred sulfation process.
The anionic surfactant may also be STnS, wherein n can define
average moles of ethoxylation. A structured cleansing phase can
include from about 5% to about 20%, by weight of the personal care
composition, of STnS. n can range from about 0 to about 3, from
about 0.5 to about 2.7, from about 1.1 to about 2.5, from about 1.8
to about 2.2, or n can be about 2. When n is less than 3, STnS can
provide improved stability, improved compatibility of benefit
agents within the personal care compositions, and increased
mildness of the personal care compositions, such described benefits
of STnS are disclosed in U.S. Patent Application Publication No.
2012/0009285.
Further, the structured cleansing phase can comprise a structuring
system, wherein the structuring system can comprise an associative
polymer and a non-associative polymer. The structuring system can
comprise from about 0.01% to about 5%, from about 0.05% to about
1%, from about 0.07% to about 0.5%, or from about 0.1% to about
0.3%, by weight of the personal care composition, of a
non-associative polymer. The structuring system can comprise from
about 0.001% to about 5%, from about 0.005% to about 0.5%, from
about 0.007% to about 0.05%, from about 0.008% to about 0.04%, or
from about 0.01% to about 0.03%, by weight of the personal care
composition, of an associative polymer. As noted herein, stability
of a personal care composition can be maintained or enhanced even
with the reduction of associative polymer with the addition of a
non-associative polymer.
Such associative polymers can be a crosslinked, alkali swellable,
associative polymer comprising acidic monomers and associative
monomers with hydrophobic end groups, whereby the associative
polymer comprises a percentage hydrophobic modification and a
hydrophobic side chain comprising alkyl functional groups. Without
intending to be limited by theory, it is believed the acidic
monomers can contribute to an ability of the associative polymer to
swell in water upon neutralization of acidic groups; and
associative monomers anchor the associative polymer into structured
surfactant hydrophobic domains, e.g., lamellae, to confer structure
to the surfactant phase and keep the associative polymer from
collapsing and losing effectiveness in a presence of an
electrolyte. The crosslinked, associative polymer can comprise a
percentage hydrophobic modification, which is a mole percentage of
monomers expressed as a percentage of a total number of all
monomers in a polymer backbone, including both acidic and other
non-acidic monomers. Percentage hydrophobic modification of the
associative polymer, hereafter % HM, can be determined by the ratio
of monomers added during synthesis, or by analytical techniques
such as proton nuclear magnetic resonance (NMR). Associative alkyl
side chains can comprise, for example, butyl, propyl, stearyl,
steareth, cetyl, lauryl, laureth, octyl, behenyl, beheneth,
steareth, or other linear, branched, saturated, or unsaturated
alkyl or alketh hydrocarbon side chains.
Associative polymers having certain % HM and certain carbon numbers
of hydrophobic end groups of alkyl side chains may also provide
significant enhancement of structure to structured surfactant
compositions, especially to compositions comprising reduced levels
of surfactant. Such associative polymers can also provide the above
structure at surprisingly low levels of polymer structurant.
Concentrations of associative polymer of up to about 5% or even 10%
are taught in the art to obtain a sufficient amount structure
(e.g., exemplary compositions of U.S. Pat. No. 7,119,059 (Librizzi,
et al.) and U.S. Pat. No. 6,897,253 (Schmucker-Castner, et al.).
Inventors have found when associative polymer % HM and an alkyl
side chain number of carbons can be optimized, structure of an
aqueous structured surfactant phase can be increased using only
less than about 3 wt %, less than about 2%, less than about 1%, and
less than about 0.2%, of an associative polymer, as a percentage of
an aqueous structured surfactant phase.
The acidic monomer can comprise any acid functional group, for
example sulfate, sulfonate, carboxylate, phosphonate, or phosphate
or mixtures of acid groups. The acidic monomer can comprise, for
example, a carboxylate, alternatively the acidic monomer is an
acrylate, including acrylic acid and/or methacrylic acid. The
acidic monomer comprises a polymerizable structure, e.g., vinyl
functionality. Mixtures of acidic monomers, for example acrylic
acid and methacrylic acid monomer mixtures, are useful.
The associative monomer can comprise a hydrophobic end group and a
polymerizable component, e.g., vinyl, which can be attached. The
hydrophobic end group can be attached to the polymerizable
component, hence to the polymer chain, by different means but can
be attached by an ether or ester or amide functionality, such as an
alkyl acrylate or a vinyl alkanoate monomer. The hydrophobic end
group can also be separated from the chain, for example, by an
alkoxy ligand such as an alkyl ether. The associative monomer can
be, for example, an alkyl ester, an alkyl (meth)acrylate, where
(meth)acrylate is understood to mean either methyl acrylate or
acrylate, or mixtures of the two.
Sometimes, the hydrophobic end group of the associative polymer can
be incompatible with the aqueous phase of the composition and can
associate with lathering surfactant hydrophobe components. Without
intending to be limited by theory, it is believed that longer alkyl
chains of structuring polymer hydrophobe end groups can increase
incompatibility with the aqueous phase to enhance structure,
whereas somewhat shorter alkyl chains having carbon numbers closely
resembling lathering surfactant hydrophobes (e.g., 12 to 14
carbons) or multiples thereof (for bilayers, e.g.) can also be
effective. An ideal range of hydrophobic end group carbon numbers
combined with an optimal percentage of hydrophobic monomers
expressed as a percentage of the polymer backbone can provide
increased structure to the lathering, structured surfactant
composition at low levels of polymer structurant.
An exemplary associative polymer can include AQUPEC.RTM. SER-300
made by Sumitomo Seika of Japan, which is an
acrylate/C.sub.10-C.sub.30 alkyl acrylate cross-polymer and
comprises stearyl side chains with less than about 1% HM.
Associative polymers can comprise about C.sub.16 (cetyl) alkyl
hydrophobic side chains with about 0.7% hydrophobic modification,
but a percentage hydrophobic modification can be up to an aqueous
solubility limit in surfactant compositions (e.g., up to 2%, 5%, or
10%). Other associative polymers can include stearyl, octyl, decyl
and lauryl side chains, alkyl acrylate polymers, polyacrylates,
hydrophobically-modified polysaccharides, hydrophobically-modified
urethanes, AQUPEC.RTM. SER-150 (acrylate/C.sub.10-C.sub.30 alkyl
acrylate cross-polymer) comprising about C.sub.18 (stearyl) side
chains and about 0.4% HM, and AQUPEC.RTM. HV-701EDR which comprises
about C.sub.8 (octyl) side chains and about 3.5% HM, and mixtures
thereof. Another exemplary associative polymer can be Stabylen 30
manufactured by 3V Sigma S.p.A., which has branched isodecanoate
hydrophobic associative side chains.
As set forth above, the structured cleansing phase of a personal
care composition can further include a non-associative polymer.
Suitable non-associative polymers can include water-dispersible
polymers with relatively uniform hydrophilic backbone lacking
hydrophobic groups. Examples of non-associative polymers can
include biopolymer polysaccharides (e.g., xanthan gum, gellan gum),
cellulosic polysaccharides (e.g., carboxymethyl cellulose,
carboxymethyl hydroxyethyl cellulose), other polysaccharides (e.g.,
guar gum, hydroxypropyl guar, and sodium alginate), and synthetic
hydrocarbon polymers (e.g., polyacrylamide and copolymers,
polyethylene oxide, polyacrylic acid copolymers).
Personal care compositions can additionally comprise a cationic
deposition polymer in one or more phases as a deposition aid for
benefit agents described herein. Non-limiting examples include
those polymers disclosed in U.S. Pat. Nos. 6,649,155; 8,349,300;
U.S.
Patent Publication 2008/0206355; and U.S. Patent Publication No.
2006/0099167A1. The personal cleansing composition may comprise a
cationic deposition polymer that forms a premix when added to the
anionic microcapsules. The cationic deposition polymer may be
included in the composition at a level from about 0.01% to about
2%, alternatively from about 1.5% to about 1.9%, alternatively from
about 1.8% to about 2.0%. The cationic deposition polymer may be a
water soluble polymer with a charge density from about 0.5
milliequivalents per gram to about 12 milliequivalents per gram.
The cationic deposition polymer used in the composition may have a
molecular weight of about 100,000 Daltons to about 5,000,000
Daltons. The cationic deposition polymer may be a low charge
density cationic polymer.
The cationic deposition polymer may be a synthetic cationic
deposition polymer. A variety of synthetic cationic deposition
polymers can be used including mono- and di-alkyl chain cationic
surfactants. In some examples, mono-alkyl chain cationic
surfactants are chosen including, for example, mono-alkyl
quaternary ammonium salts and mono-alkyl amines. In some examples,
di-alkyl chain cationic surfactants are used and include, for
example, dialkyl (14-18) dimethyl ammonium chloride, ditallow alkyl
dimethyl ammonium chloride, dihydrogenated tallow alkyl dimethyl
ammonium chloride, distearyl dimethyl ammonium chloride, dicetyl
dimethyl ammonium chloride, and mixtures thereof.
The cationic deposition polymer may be a naturally derived cationic
polymer. The term, "naturally derived cationic polymer" as used
herein, refers to cationic deposition polymers which are obtained
from natural sources. The natural sources include polysaccharide
polymers. Therefore, the naturally derived cationic polymer may be
selected from the group consisting of starches, guar, cellulose,
Cassia, locust bean, Konjac, Tara, galactomannan, tapioca, and
synthetic polymers. In a further embodiment, cationic deposition
polymers are selected from Mirapol 100S (Rhodia), Jaguar C17,
polyDADMAC, Tapioca starch (Akzo), polyTriquat, and mixtures
thereof.
The personal care composition can be optionally free of sodium
lauryl sulfate, hereinafter SLS, and can comprise at least a 70%
lamellar structure. However, in an alternative arrangement, the
structured cleansing phase can comprise at least one surfactant,
wherein the at least one surfactant includes SLS. Suitable examples
of SLS are described in U.S. Patent Application Publication No.
2010/0322878.
A personal care composition can further comprise from about 0.1% to
20%, by weight of the personal care composition, of a cosurfactant.
Cosurfactants can comprise amphoteric surfactants, zwitterionic
surfactants, or mixtures thereof. A personal care composition can
include an amphoteric surfactant and/or a zwitterionic surfactant.
Suitable amphoteric or zwitterionic surfactants can include those
described in U.S. Pat. Nos. 5,104,646 and 5,106,609.
Amphoteric surfactants can include those that can be broadly
described as derivatives of aliphatic secondary and tertiary amines
in which an aliphatic radical can be straight or branched chain and
wherein an aliphatic substituent can contain from about 8 to about
18 carbon atoms such that one carbon atom can contain an anionic
water solubilizing group, e.g., carboxy, sulfonate, sulfate,
phosphate, or phosphonate. Examples of compounds falling within
this definition can be sodium 3-dodecyl-aminopropionate, sodium
3-dodecylaminopropane sulfonate, sodium lauryl sarcosinate,
N-alkyltaurines such as the one prepared by reacting dodecylamine
with sodium isethionate according to the teaching of U.S. Pat. No.
2,658,072, N-higher alkyl aspartic acids such as those produced
according to the teaching of U.S. Pat. No. 2,438,091, and products
described in U.S. Pat. No. 2,528,378. Other examples of amphoteric
surfactants can include sodium lauroamphoacetate, sodium
cocoamphoacetate, disodium lauroamphoacetate disodium
cocodiamphoacetate, and mixtures thereof. Amphoacetates and
diamphoacetates can also be used.
Zwitterionic surfactants suitable for use can include those that
are broadly described as derivatives of aliphatic quaternary
ammonium, phosphonium, and sulfonium compounds, in which aliphatic
radicals can be straight or branched chains, and wherein an
aliphatic substituent can contain from about 8 to about 18 carbon
atoms such that one carbon atom can contain an anionic group, e.g.,
carboxy, sulfonate, sulfate, phosphate, or phosphonate. Other
zwitterionic surfactants can include betaines, including
cocoamidopropyl betaine.
Other suitable surfactants or cosurfactants that can generally be
used in a structured cleansing phase for a personal care
composition are described in McCutcheon's: Detergents and
Emulsifiers North American Edition (Allured Publishing Corporation
1947) (1986), McCutcheon's, Functional Materials North American
Edition (Allured Publishing Corporation 1973) (1992) and U.S. Pat.
No. 3,929,678 (filed Aug. 1, 1974).
The structured cleansing phase of the personal care composition can
also comprise water. The structured cleansing phase of the personal
care composition can comprise from about 10% to about 90%, from
about 40% to about 85%, or from about 60% to about 80%, by weight
of the personal care composition, of water.
Other optional additives can be included in the cleaning phase,
including for example an emulsifier (e.g., non-ionic emulsifier)
and electrolytes. Suitable electrolytes can includes an anion such
as phosphate, chloride, sulfate, citrate, and mixtures thereof and
a cation such as sodium, ammonium, potassium, magnesium, and
mixtures thereof. For example, suitable electrolytes can include
sodium chloride, ammonium chloride, sodium sulfate, ammonium
sulfate, and mixtures thereof. Other suitable emulsifiers and
electrolytes are described in U.S. Patent Application Publication
No. 2012/0009285.
B. Benefit Phase
As noted herein, personal care compositions can include a benefit
phase. The benefit phase can be hydrophobic and/or anhydrous. The
benefit phase can also be substantially free of or free of
surfactant. The benefit phase can also include one or more benefit
agents. In particular, the benefit phase can comprise from about
0.1% to about 50%, by weight of the personal care composition, of a
benefit agent.
In some examples, the benefit phase includes triglycerides. In some
examples, the triglyceride is provided as triglyceride oil.
Non-limiting examples of triglyceride oils include olive oil,
sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil,
palm oil, coconut oil, palm kernel oil, and mixtures thereof.
In some examples, the benefit phase may also include one or more of
following at levels that do not impair the development of the
clusters of the microcapsules: castor oil, mineral oil, paraffin
oil, petrolatum, lanolin and derivatives thereof, volatile and
non-volatile organosiloxanes, waxes like montan wax, ceresine, a
microcrystalline wax, hydroxyoctacosanyl hydroxystearate, beeswax,
synthetic beeswax, and silicone wax.
C. Carrier
The compositions herein may be in the form of pourable liquids
(under ambient conditions). Such compositions will therefore
typically comprise a carrier, which may be present at a level of
from about 20% to about 95%, or even from about 60% to about 85%.
The carrier may comprise water, or a miscible mixture of water and
organic solvent, and in some aspects may comprise water with
minimal or no significant concentrations of organic solvent, except
as otherwise incidentally incorporated into the composition as
minor ingredients of other essential or optional components.
The carrier may include water and/or water solutions of lower alkyl
alcohols and polyhydric alcohols. The lower alkyl alcohols useful
herein are monohydric alcohols having 1 to 6 carbons, in one
aspect, ethanol and isopropanol. The polyhydric alcohols useful
herein include propylene glycol, hexylene glycol, glycerin, and
propane diol.
D. Microcapsules
The personal care compositions herein may include microcapsules in
the cleansing and/or benefit phases. The microcapsules may be any
kind of microcapsule disclosed herein or known in the art. The
microcapsules may have a shell and a core material encapsulated by
the shell. The core material of the microcapsules may include one
or more fragrances. The shells of the microcapsules may be made
from synthetic polymeric materials or naturally-occurring polymers.
Synthetic polymers may be derived from petroleum oil, for example.
Non-limiting examples of synthetic polymers include nylon,
polyethylenes, polyamides, polystyrenes, polyisoprenes,
polycarbonates, polyesters, polyureas, polyurethanes, polyolefins,
polysaccharides, epoxy resins, vinyl polymers, polyacrylates, and
mixtures thereof. Natural polymers occur in nature and may often be
extracted from natural materials. Non-limiting examples of
naturally occurring polymers are silk, wool, gelatin, cellulose,
proteins, and combinations thereof.
The microcapsules may be friable microcapsules. A friable
microcapsule is configured to release its core material when its
shell is ruptured. The rupture may be caused by forces applied to
the shell during mechanical interactions. The microcapsules may
have a shell with a volume weighted fracture strength of from about
0.2 mega Pascals to about 15.0 mega Pascals, when measured
according to the Fracture Strength Test Method described herein, or
any incremental value expressed in 0.1 mega Pascals in this range,
or any range formed by any of these values for fracture strength.
As an example, a microcapsule may have a shell with a volume
weighted fracture strength of 0.8-15.0 mega Pascals (MPa),
alternatively from 5.0-12.0 mega Pascals (MPa), or alternatively
from 6.0-10.0 mega Pascals (MPa).
The microcapsules may have a median volume-weighted particle size
of from 2 microns to 80 microns, from 10 microns to 30 microns, or
from 10 microns to 20 microns. The microcapsules may have various
core material to shell weight ratios. The microcapsules may have a
core material to shell ratio that is greater than or equal to: 70%
to 30%, 75% to 25%, 80% to 20%, 85% to 15%, 90% to 10%, and 95% to
5%.
The microcapsules may have shells made from any material in any
size, shape, and configuration known in the art. Some or all of the
shells may include a polyacrylate material, such as a polyacrylate
random copolymer. For example, the polyacrylate random copolymer
may have a total polyacrylate mass, which includes ingredients
selected from the group including: amine content of 0.2-2.0% of
total polyacrylate mass; carboxylic acid of 0.6-6.0% of total
polyacrylate mass; and a combination of amine content of 0.1-1.0%
and carboxylic acid of 0.3-3.0% of total polyacrylate mass.
When a microcapsule's shell includes a polyacrylate material, and
the shell has an overall mass, the polyacrylate material may form
5-100% of the overall mass, or any integer value for percentage in
this range, or any range formed by any of these values for
percentage. As examples, the polyacrylate material may form at
least 5%, at least 10%, at least 25%, at least 33%, at least 50%,
at least 70%, or at least 90% of the overall mass.
Some or all of the microcapsules may have various shell
thicknesses. For at least a first group of the provided
microcapsules, each microcapsule may have a shell with an overall
thickness of 1-300 nanometers, or any integer value for nanometers
in this range, or any range formed by any of these values for
thickness. As an example, microcapsules may have a shell with an
overall thickness of 2-200 nanometers.
The microcapsules may also encapsulate one or more benefit agents.
The benefit agent(s) include, but are not limited to, cooling
sensates, warming sensates, fragrances, oils, pigments, phase
change materials, and other kinds of benefit agent known in the
art, in any combination. In some examples, the fragrance
encapsulated may have a C log P of less than 4.5 or a C log P of
less than 4. Alternatively the fragrance encapsulated may have a C
log P of less than 3. In some examples, the microcapsule may be
anionic, cationic, zwitterionic, or have a neutral charge. The
benefit agents(s) may be in the form of solids and/or liquids. The
benefit agent(s) may be any kind of fragrance(s) known in the art,
in any combination.
The microcapsules may encapsulate a partitioning modifier in
addition to the benefit agent. Non-limiting examples of
partitioning modifiers include mono, di- and tri-esters of
C.sub.4-C.sub.24 fatty acids and glycerin; isopropyl myristate,
soybean oil, hexadecanoic acid, methyl ester, isododecane, and
combinations thereof, in addition to the encapsulated. The oil
soluble material may have a C log P about 4 or greater, at least 5
or greater, at least 7 or greater, or at least 11 or greater.
Microcapsules may also have varying ratios of the partitioning
modifier to the benefit so as to make different populations of
microcapsules that may have different bloom patterns. Such
populations may also incorporate different perfume oils so as to
make populations of microcapsules that display different bloom
patterns and different scent experiences.
The microcapsule's shell may comprise a reaction product of a first
mixture in the presence of a second mixture comprising an
emulsifier, the first mixture comprising a reaction product of i)
an oil soluble or dispersible amine with ii) a multifunctional
acrylate or methacrylate monomer or oligomer, an oil soluble acid
and an initiator, the emulsifier comprising a water soluble or
water dispersible acrylic acid alkyl acid copolymer, an alkali or
alkali salt, and optionally a water phase initiator. In some
examples, said amine is an aminoalkyl acrylate or aminoalkyl
methacrylate.
The microcapsules may include a core material and a shell
surrounding the core material, wherein the shell comprises: a
plurality of amine monomers selected from the group consisting of
aminoalkyl acrylates, alkyl aminoalkyl acrylates, dialkyl
aminoalkyl acrylates, aminoalkyl methacrylates, alkylamino
aminoalkyl methacrylates, dialkyl aminoalkyl methacrylates,
tertiarybutyl aminethyl methacrylates, diethylaminoethyl
methacrylates, dimethylaminoethyl methacrylates, dipropylaminoethyl
methacrylates, and mixtures thereof; and a plurality of
multifunctional monomers or multifunctional oligomers.
Processes for making microcapsules are well known. Various
processes for microencapsulation, and exemplary methods and
materials, are set forth in U.S. Pat. Nos. 6,592,990; 2,730,456;
2,800,457; 2,800,458; 4,552,811; and U.S. 2006/0263518 A1. U.S.
Patent Publication Nos. 2012/0276175, 2011/0268802, 2011/0269657,
2011/0269658, 2011/268778 are also hereby incorporated by
reference.
In some examples, the microcapsules may be made by using a process
comprising the steps of: 1) preparing an oligomeric composition
comprising the reaction product of, or obtainable by reacting
together: a) a polyamine component in the form of melamine or of a
mixture of melamine and at least one C1-4 compound comprising two
NH2 functional groups; b) an aldehyde component in the form of a
mixture of glyoxal, a C.sub.4_6 2,2-dialkoxyethanal and optionally
a glyoxalate, said mixture having a molar ratio glyoxal/C.sub.4_6
2,2-dialkoxy-ethanal comprised between about 1/1 and 10/1; and c) a
protic acid catalyst; 2) preparing an oil-in-water dispersion,
wherein the droplet size is comprised between 1 and 600 mih, and
comprising: i) an oil; ii) a water medium; iii) at least an
oligomeric composition as obtained in step 1); iv) at least a
cross-linker selected amongst: A) C4-Ci2 aromatic or aliphatic di-
or tri-isocyanates and their biurets, triurets, trimers and
trimethylol propane-adduct; and/or B) a di- or tri-oxiran compounds
of formula A-(oxiran-2-ylmethyl) n wherein n stands for 2 or 3 and
A represents a C.sub.2-C.sub.6 group optionally comprising from 2
to 6 nitrogen and/or oxygen atoms; v) optionally a C1-4 compound
comprising two NH2 functional groups; 3) heating said dispersion;
4) cooling said dispersion; and 5) optionally adding to the
dispersion of step 4) at least one cationic polymer and/or urea or
ethylene urea; and 6) optionally drying the final dispersion to
obtain the dried core-shell microcapsule. The microcapsules
described in the following publications/patents are also hereby
incorporated by reference: U.S. Pat. No. 8,835,002 and U.S. Patent
Publication No. 2014/0322283.
In some examples, the microcapsules may be prepared by the
following: 1) preparing an oligomeric composition comprising the
reaction product of, or obtainable by reacting together: a) a
polyamine component in the form of melamine or of a mixture of
melamine and at least one C.sub.1-4 compound comprising two
NH.sub.2 functional groups; b) an aldehyde component in the form of
a mixture of glyoxal, a C.sub.4-6 2,2-dialkoxy-ethanal and
optionally a glyoxalate, said mixture having a molar ratio
glyoxal/C.sub.4-6 2,2-dialkoxy-ethanal comprised between about 1/1
and 10/1; and c) a protic acid catalyst; 2) preparing an
oil-in-water dispersion, wherein the droplet size is comprised
between 1 and 600 .mu.m, and comprising: i) an oil; ii) a water
medium; iii) at least an oligomeric composition as obtained in step
1); iv) at least a cross-linker selected amongst: A)
C.sub.4-C.sub.12 aromatic or aliphatic di- or tri-isocyanates and
their biurets, triurets, trimers and trimethylol propane-adduct;
and/or B) a di- or tri-oxiran compounds of formula
A-(oxiran-2-ylmethyl).sub.n wherein n stands for 2 or 3 and A
represents a C.sub.2-C.sub.6 group optionally comprising from 2 to
6 nitrogen and/or oxygen atoms; v) optionally a C.sub.1-4 compound
comprising two NH.sub.2 functional groups; 3) heating said
dispersion; 4) cooling said dispersion; and 5) optionally adding to
the dispersion of step 4) at least one cationic polymer and/or urea
or ethylene urea; and 6) optionally drying the final dispersion to
obtain the microcapsule.
The microcapsules may also be prepared by: 1) preparing an
oil-in-water dispersion, wherein the droplet size is comprised
between 1 and 600.mu..eta., and comprising at least an oligomeric
composition as defined below; 2) optionally adding to the
dispersion a C compound comprising two NH.sub.2 functional groups;
3) heating said dispersion; 4) cooling said dispersion; and 5)
optionally drying the final dispersion to obtain the microcapsule.
The oligomeric composition may be prepared by a reaction
comprising: 1) a poly amine component in the form of melamine or of
a mixture of melamine and at least one C compound comprising two
N3/4 functional groups; 2) an aldehyde component in the form of a
mixture of glyoxal, a C.sub.4_6 2,2-dialkoxy-ethanal and optionally
a glyoxalate, said mixture having a molar ratio glyoxal/C.sub.4-6
2,2-dialkoxy-ethanal comprised between about 1/1 and 10/1; and 3) a
protic acid catalyst. "Glyoxal" is understood to mean both the free
di-aldehyde form (e.g. OHC--CHO) and the hydrated forms (e.g.
(HO).sub.2HC--CHO). "Glyoxalate" is understood to mean the
glyoxalic acid or an alkaline salt of glyoxalic acid (such as
OHC--COONa or OHC--COOK) or mixture thereof. The term "glyoxalate"
is also understood to mean both the free aldehyde form (i.e.
OHC--COOH) and the hydrated form (e.g. (HO).sub.2HC--COOH or
(HO).sub.2HC--COONa). Non-limiting examples of C compound
comprising two NH2 functional groups include urea,
IH-I,2,4-triazole-3,5-diamine and mixtures thereof.
The microcapsule may be spray-dried to form spray-dried
microcapsules. The composition may also contain one or more
additional delivery systems for providing one or more benefit
agents, in addition to the microcapsules. The additional delivery
system(s) may differ in kind from the microcapsules. For example,
wherein the microcapsule encapsulates a fragrance, the additional
delivery system may be an additional fragrance delivery system,
such as a moisture-triggered fragrance delivery system.
Non-limiting examples of moisture-triggered fragrance delivery
systems include cyclic oligosaccharide, starch (or other
polysaccharide material), starch derivatives, and combinations
thereof. Said polysaccharide material may or may not be
modified.
The compositions may also include a parent fragrance and one or
more encapsulated fragrances that may or may not differ from the
parent fragrance. For example, the composition may include a parent
fragrance and a non-parent fragrance. A parent fragrance refers to
a fragrance that is dispersed throughout the composition and is
typically not encapsulated when added to the composition. Herein, a
non-parent fragrance refers to a fragrance that differs from a
parent fragrance included within the composition and is
encapsulated with an encapsulating material prior to inclusion into
the composition. Non-limiting examples of differences between a
fragrance and a non-parent fragrance include differences in
chemical make-up.
Other Ingredients
Additional other ingredients can also be added to the personal care
composition for treatment of the skin, or to modify the aesthetics
of the personal care composition as is the case with perfumes,
colorants, dyes or the like. Optional materials useful in products
herein can be categorized or described by their cosmetic and/or
therapeutic benefit or their postulated mode of action or function.
However, it can be understood that actives and other materials
useful herein can, in some instances, provide more than one
cosmetic and/or therapeutic benefit or function or operate via more
than one mode of action. Therefore, classifications herein can be
made for convenience and cannot be intended to limit an ingredient
to particularly stated application or applications listed. A
precise nature of these optional materials, and levels of
incorporation thereof, will depend on the physical form of the
composition and the nature of the cleansing operation for which it
is to be used. The other materials can usually be formulated at
about 6% or less, about 5% or less, about 4% or less, about 3% or
less, about 2% or less, about 1% or less, about 0.5% or less, about
0.25% or less, about 0.1% or less, about 0.01% or less, or about
0.005% or less of the personal care composition.
To further improve stability under stressful conditions such as
high temperature and vibration, densities of separate phases can be
adjusted such that they can be substantially equal. To achieve
this, low density microspheres can be added to one or more phases
of the personal care composition. Examples of personal care
compositions that comprise low density microspheres are described
in a patent application published on May 13, 2004 under U.S. Patent
Publication No. 2004/0092415A1 entitled "Striped Liquid Personal
Cleansing Compositions Containing A Cleansing Phase and A Separate
Phase with Improved Stability," filed on Oct. 31, 2003 by Focht, et
al.
Other non-limiting ingredients that can be used in the personal
care compositions include components that can be selected from the
group consisting of thickening agents; preservatives;
antimicrobials; fragrances; chelators (e.g., such as those
described in U.S. Pat. No. 5,487,884 issued to Bisset, et al.);
sequestrants; vitamins (e.g., Retinol); vitamin derivatives (e.g.,
tocophenyl actetate, niacinamide, panthenol); sunscreens;
desquamation actives (e.g., such as those described in U.S. Pat.
Nos. 5,681,852 and 5,652,228 issued to Bisset);
anti-wrinkle/anti-atrophy actives (e.g., N-acetyl derivatives,
thiols, hydroxyl acids, phenol); anti-oxidants (e.g., ascorbic acid
derivatives, tocophenol) skin soothing agents/skin healing agents
(e.g., panthenoic acid derivatives, aloe vera, allantoin); skin
lightening agents (e.g., kojic acid, arbutin, ascorbic acid
derivatives) skin tanning agents (e.g., dihydroxyacteone);
anti-acne medicaments; essential oils; sensates; pigments;
colorants; pearlescent agents; interference pigments (e.g., such as
those disclosed in U.S. Pat. No. 6,395,691 issued to Liang Sheng
Tsaur, U.S. Pat. No. 6,645,511 issued to Aronson, et al., U.S. Pat.
No. 6,759,376 issued to Zhang, et al, U.S. Pat. No. 6,780,826
issued to Zhang, et al.) particles (e.g., talc, kolin, mica,
smectite clay, cellulose powder, polysiloxane, silicas, carbonates,
titanium dioxide, polyethylene beads) hydrophobically modified
non-platelet particles (e.g., hydrophobically modified titanium
dioxide and other materials described in a commonly owned, patent
application published on Aug. 17, 2006 under Publication No.
2006/0182699A, entitled "Personal Care Compositions Containing
Hydrophobically Modified Non-platelet particle filed on Feb. 15,
2005 by Taylor, et al.) and mixtures thereof. The multiphase
personal care composition can comprise from about 0.1% to about 4%,
by weight of the personal care composition, of hydrophobically
modified titanium dioxide. Other such suitable examples of such
skin actives are described in U.S. Patent Application Publication
No. 2012/0009285. Other ingredients can be most typically those
materials approved for use in cosmetics and that are described in
the CTFA Cosmetic Ingredient Handbook, Second Edition, The
Cosmetic, Toiletries, and Fragrance Association, Inc. 1988,
1992.
III. FORMING A PREMIX
The cationic deposition polymer and the anionic microcapsule are
mixed to form a premix before addition to the personal cleansing
composition comprising at least one anionic surfactant and a
carrier.
The weight ratio of the anionic microcapsule to the cationic
deposition polymer (based on the dry weight of the anionic
microcapsules and the dry weight of the cationic deposition
polymer) is from about 0.5:30 to about 20:1, from about 5:15 to
about 15:1, and from about 5:1 to about 12:1. It is believed that
too much cationic polymer may not provide enhanced and/or prolonged
benefits to the benefit agent microcapsules due to the formation of
excess cationic polymer coating on the capsule wall. This excess
coating may prevent the microcapsule wall from breaking and
releasing the benefit agents.
The cationic deposition polymer may include those listed above with
respect to the structured cleansing phase. The cationic deposition
polymer premixed with the microcapsule may be the same or different
than any included in the structured cleansing phase. The cationic
deposition polymer can be, for example, polyvinyl formamide. The
microcapsule can be premixed to form a slurry comprising, by weight
of the slurry, from about 0.01% to about 5%, from about 0.05% to
about 2% or even from about 0.1% to about 1%, of a polyvinyl
formamide; from about 0% to about 5% MgCl.sub.2; from about 0% to
about 1% xanthan gum; and a carrier.
The cationic deposition polymer for use in the microcapsule premix
can have a molecular weight from about 1,000 Da to about 50,000,000
Da; from about 5,000 Da to about 25,000,000 Da; from about 10,000
Da to about 10,000,000 Da; or even from about 300,000 Da to about
2,000,000. The cationic deposition polymer can also have a charge
density from about 1 meq/g to about 23 meq/g, from about 1 meq/g to
about 16 meq/g, from about 1 meq/g to about 10 meq/g, or from 1
meq/g to about 4 meq/g.
IV. METHOD OF MANUFACTURE
The personal cleansing compositions herein may be prepared by a
process comprising: 1) combining an anionic microcapsule with a
cationic deposition polymer to form a premix; and 2) adding the
premix to a composition comprising a surfactant, a benefit agent
comprising a triglyceride, and a carrier.
V. PRODUCT FORMS
The personal cleansing compositions may be in the form of rinse-off
products or leave-on products, and can be formulated in a wide
variety of product forms, including but not limited to creams,
gels, emulsions, mousses, body washes, shampoos, conditioners, and
sprays.
As noted herein, the personal cleansing composition may include a
structured cleansing phase and a benefit phase. In some examples,
the structured cleansing phase and the benefit phase are in
physical contact. In some examples, the personal cleansing
composition may be a multiphase personal cleansing composition
where the structured cleansing phase and the benefit phase are be
blended or mixed to a significant degree, but remain physically
distinct such that the physical distinctiveness is undetectable to
the naked human eye.
In some examples, the personal cleansing composition may be a
multiphase personal cleansing composition where the structured
cleansing phase and the benefit phase are made to occupy separate
but distinct physical spaces inside a package in which the phases
are stored. In such examples, the structured cleansing phase and
the benefit phase can be stored such that the phases are not in
direct contact with one another. In some examples, the personal
cleansing composition can be a multiphase personal cleansing
composition where the structured cleansing phase and the benefit
phase are in physical contact and have a striped or marbled
configuration.
In some examples, the personal cleansing composition can include a
combination of one or more of the above multiphase personal
cleansing compositions. In some examples, one blended multiphase
personal cleansing composition can be stacked as stripes with
another blended multiphase personal cleansing composition. And in
other examples, the blended multiphase personal cleansing
compositions distinguishable by color can be stacked as stripes
wherein the blended multiphase personal cleansing compositions can
be otherwise similar.
VI. TEST METHODS
It is understood that the test methods that are disclosed in the
Test Methods Section of the present application should be used to
determine the respective values of the parameters of Applicants'
invention as such invention is described and claimed herein.
C log P
The "calculated log P" (C log P) is determined by the fragment
approach of Hansch and Leo (cf., A. Leo, in Comprehensive Medicinal
Chemistry, Vol. 4, C. Hansch, P G Sammens, J. B. Taylor, and C A
Ramsden, Eds. P. 295, Pergamon Press, 1990, incorporated herein by
reference). C log P values may be calculated by using the "C LOG P"
program available from Daylight Chemical Information Systems Inc.
of Irvine, Calif. U.S.A.
Boiling Point
Boiling point is measured by ASTM method D2887-04a, "Standard Test
Method for Boiling Range Distribution of Petroleum Fractions by Gas
Chromatography," ASTM International.
Zeta Potential
(1) Equipment specifications: Malvern Zeatasizer Nano Model ZEN3600
Sample cell, disposable capillary cell (green cell) (2) Use Duke
standards to measure the PSD, and use it to measure the zeta
potential to assure that the instrument is functioning properly.
(3) Flush a DTS1060 capillary cell with 1-2 mL ethanol, then with
DI water to prepare the capillary cell. (4) Sample preparation:
first, filter 20 mL DI water through 0.2 micron filter into a 20 mL
vial. Add 1 drop (50 microliters of 30 wt % solids suspension into
the vial and invert the sample back and forth gently until the
particulate suspension is homogeneously dispersed in the vial.
Next, rinse a DTS1060 green disposable zeta cell with 1-2 mL of DI
water, then use a syringe to transfer the sample solution from the
vial into the zeta cell, making sure that no air bubbles are
present in the cell. Fill the cell to the top, then place a cap on
the cell outlet and inlet (again making sure no air bubbles are
present in the sample cell). Then, place the cell in the sample
chamber, with the electrodes facing the sides of the system.
Finally, place the sample cell in the instrument. (5) Conditions
for the run: a. Refractive index=1.35 (this number may vary for
suspensions. One can measure the refractive index for any
particulate suspension using a refractometer) b. Temperature=25
degrees Centigrade c. Equilibration time=1 minute d. Smoluchowski
model to be used to calculate the zeta potential (6) Measure each
sample in triplicate. The result from the instrument is reported as
Zeta Potential in milliVolts, with no extrapolation.
VII. EXAMPLES
The following examples illustrate the present invention. The
exemplified compositions may be prepared by conventional
formulation and mixing techniques. It will be appreciated that
other modifications of the present invention within the skill of
those in the art may be undertaken without departing from the
spirit and scope of this invention. All parts, percentages, and
ratios herein are by weight unless otherwise specified. Some
components may come from suppliers as dilute solutions. The amount
stated reflects the weight percent of the active material, unless
otherwise specified.
The following are non-limiting examples of microcapsules and
compositions described herein.
TABLE-US-00001 I: Personal Care Example Example Example Composition
A B C Sodium Trideceth Sulfate 9.59% 9.08% 9.08% (sulfated from
Trideceth-2, Stepan) Cocoamidopropyl Betaine 2.87% 2.71% 2.71%
Trideceth-3 1.53% 1.45% 1.45% Sodium Chloride 4.42% 4.19% 4.19%
Guar Hydroxypropyltrimonium 0.50% 0.47% 0.47% Chloride (N-Hance
CG-17 from Aqualon) Xanthan Gum (Keltrol 1000 0.34% 0.32% 0.32%
from CP Kelco) Acrylates/C10-30 Alkylacrylate 0.03% 0.029% 0.029%
Cross Polymer (Aqupec SER- 300C from Sumitomo) Methyl chloro
isothiazolinone 0.033% 0.033% 0.033% and methyl isothiazolinone
(Kathon CG, Rohm & Haas) EDTA (Dissolvine NA 2x) 0.31% 0.31%
0.31% Sodium Benzoate 0.14% 0.14% 0.14% Perfume 1.0% 1.0% 1.0% RBD
Soybean Oil 4.85% 9.70% -- Glyceryl Oleate 0.05% 0.10% 0.20% BHT
0.1% 0.20% -- Petrolatum -- -- 9.8% Perfume Microcapsule Slurry
0.8% 0.8% 0.8% of Examples 1, 2, 3, 4 or 5 Citric Acid, titrate pH
= pH = pH = 5.7 .+-. 0.2 5.7 .+-. 0.2 5.7 .+-. 0.2 Water and minors
Q.S. Q.S. Q.S.
Example 1. Nonionic Microcapsule
An oil solution, consisting of 75 g Fragrance Oil scent A, 75 g of
Isopropyl Myristate, 0.6 g DuPont Vazo-52, and 0.4 g DuPont
Vazo-67, is added to a 35.degree. C. temperature controlled steel
jacketed reactor, with mixing at 1000 rpm (4 tip, 2'' diameter,
flat mill blade) and a nitrogen blanket applied at 100 cc/min. The
oil solution is heated to 75.degree. C. in 45 minutes, held at
75.degree. C. for 45 minutes, and cooled to 60.degree. C. in 75
minutes. A second oil solution, consisting of 37.5 g Fragrance Oil,
0.5 g tertiarybutylaminoethyl methacrylate, 0.4 g 2-carboxyethyl
acrylate, and 20 g Sartomer CN975 (hexafunctional urethane-acrylate
oligomer) is added when the first oil solution reached 60.degree.
C. The combined oils are held at 60.degree. C. for an additional 10
minutes. Mixing is stopped and a water solution, consisting of 56 g
of 5% active polyvinyl alcohol Celvol 540 solution in water, 244 g
water, 1.1 g 20% NaOH, and 1.2 g DuPont Vazo-68WSP, is added to the
bottom of the oil solution, using a funnel. Mixing is again
started, at 2500 rpm, for 60 minutes to emulsify the oil phase into
the water solution. After milling is completed, mixing is continued
with a 3'' propeller at 350 rpm. The batch is held at 60.degree. C.
for 45 minutes, the temperature is increased to 75.degree. C. in 30
minutes, held at 75.degree. C. for 4 hours, heated to 90.degree. C.
in 30 minutes and held at 90.degree. C. for 8 hours. The batch is
then allowed to cool to room temperature. The finished
microcapsules have a median particle size of 6.4 microns, a
broadness index of 1.3, and a zeta potential of negative 0.5
millivolts, and a total scent A concentration of 27.6 wt %.
Example 2. Anionic Microcapsule, Large Particle Size
Capsules are made using identical materials, compositions, and
process conditions as in Example 1 with the following exceptions: 1
gram of Vazo-52, 0.8 grams of Vazo-67, 0.3 grams of
tertiarybutylaminoethyl methacrylate, 0.25 grams of 2-carboxyethyl
acrylate, and 12 grams of Sartomer CN975 as compositional
differences in the oil phase; and 22 grams of 25% active Colloid
351, and 308 grams of water as compositional differences in the
water phase. All other mixing and process conditioner remains the
same. The finished microcapsules have a median particle size of
10.7 microns, a broadness index of 1.5, and a zeta potential of
negative 60 milivolts, and a total scent A concentration of 34.9 wt
%.
Example 3. Anionic Microcapsule, Small Particle Size
Capsules are made using identical materials, compositions, and
process conditions as in Example 1 with the following exceptions: 1
gram of Vazo-52, 0.8 grams of Vazo-67, 1.5 grams of
tertiarybutylaminoethyl methacrylate, 1.2 grams of 2-carboxyethyl
acrylate, and 60 grams of Sartomer CN975 as compositional
differences in the oil phase; and 68 grams of 25% active Colloid
351, and 282 grams of water as compositional differences in the
water phase. All other mixing and process conditioner remains the
same. The finished microcapsules have a median particle size of 1.4
microns, a broadness index of 1.2, and a zeta potential of negative
60 milivolts, and a total scent A concentration of 20.7 wt %.
Example 4. Anionic Microcapsule
Capsules are made using identical materials, compositions, and
process conditions as in Example 2 with the following exceptions: 1
gram of tertiarybutylaminoethyl methacrylate, 0.8 grams of
2-carboxyethyl acrylate, and 40 grams of Sartomer CN975 as
compositional differences in the oil phase; and 22 grams of 25%
active Colloid 351, and 282 grams of water as compositional
differences in the water phase. All other mixing and process
conditioners remain the same. The finished microcapsules have a
median particle size of 4.8 microns, a broadness index of 1.3, and
a zeta potential of negative 60 milivolts, and a total scent A
concentration of 23.5 wt %.
Example 5. 90 wt % Core/10 wt % Wall, Scent A Capsules, 20%
Partitioning Modifier
An oil solution, consisting of 128.4 g of perfume Oil, 32.1 g
isopropyl myristate, 0.86 g DuPont Vazo-67, 0.69 g Wako Chemicals
V-501, is added to a 35.degree. C. temperature controlled steel
jacketed reactor, with mixing at 1000 rpm (4 tip, 2'' diameter,
flat mill blade) and a nitrogen blanket applied at 100 cc/min. The
oil solution is heated to 70.degree. C. in 45 minutes, held at
75.degree. C. for 45 minutes, and cooled to 50.degree. C. in 75
minutes. This mixture is hereafter referred to as oil solution
A.
In a reactor vessel, an aqueous solution is prepared consisting of
300 g of deionized water to which is dispersed in 2.40 grams of
Celvol 540 polyvinyl alcohol at 25.degree. C. The mixture is heated
to 85.degree. C. and held there for 45 minutes. The solution is
cooled to 30.degree. C. 1.03 grams of Wako Chemicals V-501
initiator is added, along with 0.51 grams of a 40% sodium hydroxide
solution. The solution is then heated to 50.degree. C., and the
solution is maintained at that temperature.
To oil solution A, add 0.19 grams of tert-butyl amino ethyl
methacrylate (Sigma Aldrich), 0.19 grams of beta-carboxy ethyl
acrylate (Sigma Aldrich), and 15.41 grams of Sartomer CN975
(Sartomer, Inc.). Mix the acrylate monomers into the oil phase for
10 minutes. This mixture is hereafter referred to as oil solution
B. Use a Caframo mixer with a 4-blade pitched turbine agitator.
Start a nitrogen blanket on top of the aqueous solution in reactor.
Start transferring oil solution B into the aqueous solution in the
reactor with minimal mixing. Increase the agitation of mixing to
1800-2500 rpm for a period of 60 minutes to emulsify the oil phase
into the water solution. After milling is completed, mixing is
continued with a 3'' propeller at 350 rpm. The batch is then held
at 50.degree. C. for 45 minutes. The temperature is then increased
to 75.degree. C. in 30 minutes, held at 75.degree. C. for 4 hours,
heated to 95.degree. C. in 30 minutes and held at 95.degree. C. for
6 hours. The batch is then allowed to cool to room temperature.
A perfume encapsulated, called Scent A, is utilized to prepare
Examples 1-5. The table below lists the ingredients, and their
properties. Table 5 provides the C log P breakdown of the perfume
oil encapsulated.
TABLE-US-00002 Boiling Dispersion H-Bond Polarity Point Scent A
ClogP (MPa.sup.1/2) (MPa.sup.1/2) (MPa.sup.1/2) (.degree. C.)
3,6-Nonadien-1-ol 2.45 15.76 14.28 4.39 213 Allyl Caproate 3.03
15.63 6.25 4.13 198 Allyl Heptoate 3.57 15.6 6.04 3.81 216 Beta
Gamma Hexenol 1.3 15.79 14.73 5.45 155 Cis 3 Hexenyl Acetate 2.18
15.75 6.57 4.55 167 Cis-6-Nonen-1-OL FCC 2.7 15.78 13.46 4.01 214
Cyclo Galbanate 2.54 17.15 6.84 3.9 273 Cymal 3.62 17.88 4.16 5.6
290 Dihydro Myrcenol 3.08 15.54 10.78 3.6 195 Dimethyl Benzyl
Carbinyl Butyrate 4.09 17.76 4.39 4.99 270 Ethyl 2 Methyl
Pentanoate 2.55 15.58 5.97 3.64 157 Ethyl Acetoacetate 0.15 16.16
8.7 8.12 179 Ethyl Caproate FCC 2.62 15.86 6.26 3.61 165 Ethyl
Maltol 0.17 18.14 9.66 6.3 274 Ethyl Oenanthate 3.2 15.71 6.09 3.27
183 Ethyl-2-Methyl Butyrate 1.91 15.68 6.18 3.92 133 Florhydral
3.59 18.04 4.19 5.57 295 Hexamethylindanopyran 5.43 15.68 3.59 6.11
398 Gamma Decalactone 3.23 17.32 6.36 11.78 211 Hexyl Acetate 2.64
15.86 6.44 3.7 165 Ionone Beta 4.02 16.54 4.37 5.65 267
Jasmolactone 2.36 17.59 6.44 6.47 219 Liffarome 2.14 15.61 7.32
3.23 167 Ligustral Or Triplal 1.78 17.28 5.13 7.17 199 Linalool
2.44 15.38 11.14 3.72 204 Melonal 2.09 15.55 4.86 6.65 182 Nectaryl
4.18 17.76 4.33 8.31 319 Para Hydroxy Phenyl Butanone 1.58 18.62
12.32 8.72 294 Pino Acetaldehyde 2.98 17.06 4.96 6.03 261 Prenyl
Acetate 1.12 15.42 6.37 5.32 145 Thesaron 3.84 16.65 5.07 4.57 216
Undecalactone 3.75 17.24 6.21 11.1 228 Undecavertol 3.06 15.41
10.39 3.49 242 Verdox 3.87 16.96 5.34 3.66 223 Verdural B Extra
3.21 15.46 5.71 3.74 193
Examples D-L
The base surfactant composition can be prepared by standard mixing
technique. First, add water to a container. Then, add the following
ingredients with continuous mixing: sodium chloride, guar
hydroxypropyl trimoium chloride, cocoamidopropyl betaine, sodium
trideceth sulfate sodium lauryl sulfate. Prepare a premix of
acrylates/C10-C30 alkylacrylates cross polymer and Xanthan gum with
trideceth-3. Add the premix to the main container with mixing. Add
EDTA, sodium Benzoate to the main container. Adjust the pH to 5.7
using 50% citric acid solution. Add Kathon CG. Keep mixing until
homogeneous.
TABLE-US-00003 Base Surfactant Sodium Trideceth Sulfate 10.3%
(sulfated from Trideceth-2, Stepan) Cocoamidopropyl Betaine 3.08%
Trideceth-3 1.64% Sodium Chloride 4.75% Guar Hydroxypropyltrimonium
Chloride 0.53% (N-Hance CG-17 from Aqualon) Xanthan Gum 0.37%
(Keltrol 1000 from CP Kelco) Acrylates/C10-30 Alkylacrylate Cross
0.033% Polymer (Aqupec SER-300C from Sumitomo) Methyl chloro
isothiazolinone and methyl 0.0007% isothiazolinone (Kathon CG, Rohm
& Haas) EDTA (Dissolvine NA 2x) 0.15% Sodium Benzoate 0.34%
Citric Acid, titrate pH = 5.7 Water and Minors Q.S.
Examples D-L can be prepared with standard mixing techniques.
First, add the base surfactant to a container. Then, prepare a
premix of soybean oil, glyceryl monooleate, BHT in a separate
container by heating to 50.degree. C. with mixing. Then, add the
premix to the surfactant phase with continuous mixing. Then add the
perfume, and PMC slurry (where utilized) into the batch. Keep
mixing until homogenous.
TABLE-US-00004 Example D Example E Example F I) Base Surfactant
91.8% 91.8% 91.8% II) Lipid Phase RBD Soybean Oil 6.79% 6.79% 6.79%
Glyceryl Oleate 0.07% 0.07% 0.07% BHT 0.14% 0.14% 0.14% III)
Perfume and PMC Neat Perfume 1.2% 1.0% 1.0% Perfume Microcapsule A
-- 0.2% -- (anionic microcapsules) Perfume Microcapsule B -- --
0.2% (premix containing anionic microcapsules & cationic
polymer) Arm Wash Perfume Headspace Testing Results Initial Perfume
GC 1 1.3 1.9 Headspace (index to No Microcapsule Control) Perfume
GC 1 1.4 1.3 Headspace after one Hour (pre-rub) (index to No
Microcapsule Control) Perfume GC 1 1.5 10.6 Headspace after one
Hour (post-rub) (index to No Microcapsule Control) Product to Water
Dilution (1:9) Ratio Optical Microscopy Lipid Coacervate Observed
individual Observed (10.times. DIC Mode) Only microcapsules
microcapsule floating in aqueous clusters within solution the
lipid/polymer coacervate Example G No PMC Example Example Example
Example Example Control H I J K L IV) Base Surfactant 91.8% 91.37%
91.29% 91.37% 91.27% 91.27% V) Lipid Phase RBD Soybean Oil 6.79%
6.79% 6.79% 6.79% 6.79% 6.79% Glyceryl Oleate 0.07% 0.07% 0.07%
0.07% 0.07% 0.07% BHT 0.14% 0.14% 0.14% 0.14% 0.14% 0.14% VI)
Perfume and PMC Neat Perfume 1.2% 1.0% 1.0% 1.0% 1.0% 1.0% Perfume
Microcapsule A -- 0.63% -- -- -- -- (based on total oil content)
(0.2% oil) (anionic PMC) Perfume Microcapsule B -- -- 0.71% (based
on total oil content) (0.2% oil) (nonionic PMC) Perfume
Microcapsule C 0.63% (based on total oil content) (0.2% oil)
(cationic PMC) Perfume Microcapsule D 0.73% (based on total oil
content) (0.2% oil) (anionic PMC + cationic polymer) Perfume
Microcapsule E 0.73% (based on total oil content) (0.2% oil)
(anionic PMC + cationic polymer) Product to Water Dilution (1:9)
Ratio Optical Microscopy No No No No Yes Yes (10.times. DIC Mode)
PMC PMC Clustering Clustering Clustering Clustering with Coacervate
Control Corresponding FIG. 1 2 3 4 5 6
Additional information on the microcapsules utilized in Examples
H-L is listed below.
TABLE-US-00005 Perfume Microcapsule A (anionic PMC) Properties
Particle size (volume average) 11.43 microns Particle size
distribution (volume average) 1.75 pH 5.82 % Total Oil 31.58% %
Solids 44.65% Core Description 80/20 Perfume/Isopropyl Myristate
Core/Wall Ratio 90/10 Colloid Descriptor 0.8% PVOH Others All beta
C - anionic
TABLE-US-00006 Perfume Microcapsule B (nonionic PMC) Properties
Particle size (volume average) 11.15 microns Particle size
distribution (volume average) 1.59 pH 5.57 % Total Oil 28.15% %
Solids 46.30% Core Description 70/30 Perfume/Isopropyl Myristate
Core/Wall Ratio 90/10 Colloid Descriptor 0.8% PVOH Others
CN975/TBAEMA/Beta-C
TABLE-US-00007 Perfume Microcapsule C (cationic PMC) Properties
Particle size (volume average) 11.15 microns Particle size
distribution (volume average) 1.79 pH 6.18 % Total Oil 31.86% %
Solids 45.03% Core Description 80/20 Perfume/Isopropyl Myristate
Core/Wall Ratio 90/10 Colloid Descriptor 0.8% PVOH Others All
TBAEMA-cationic
TABLE-US-00008 Perfume Microcapsule D (anionic PMC + cationic
polymer) Particle size (volume average) 19.66 microns Particle size
distribution (volume average) 1.56 pH 5.28 % Total Oil 27.26% Shell
Descriptor Melamine Formaldehyde Cationic Deposition Polymer:
Polyvinyl 0.58% Formamide
TABLE-US-00009 Perfume Microcapsule E (anionic PMC + cationic
polymer) Particle size (volume average) 17.64 microns Particle size
distribution (volume average) 1.54 pH 5.33 % Total Oil 27.29% Shell
Descriptor Melamine Formaldehyde Cationic Deposition Polymer:
Polyvinyl 0.58% Formamide
It should be understood that every maximum numerical limitation
given throughout this specification includes every lower numerical
limitation, as if such lower numerical limitations were expressly
written herein. Every minimum numerical limitation given throughout
this specification will include every higher numerical limitation,
as if such higher numerical limitations were expressly written
herein. Every numerical range given throughout this specification
will include every narrower numerical range that falls within such
broader numerical range, as if such narrower numerical ranges were
all expressly written herein.
The dimensions and values disclosed herein are not to be understood
as being strictly limited to the exact numerical values recited.
Instead, unless otherwise specified, each such dimension is
intended to mean both the recited value and a functionally
equivalent range surrounding that value. For example, a dimension
disclosed as "40 mm" is intended to mean "about 40 mm."
Every document cited herein, including any cross referenced or
related patent or application and any patent application or patent
to which this application claims priority or benefit thereof, is
hereby incorporated herein by reference in its entirety unless
expressly excluded or otherwise limited. The citation of any
document is not an admission that it is prior art with respect to
any invention disclosed or claimed herein or that it alone, or in
any combination with any other reference or references, teaches,
suggests or discloses any such invention. Further, to the extent
that any meaning or definition of a term in this document conflicts
with any meaning or definition of the same term in a document
incorporated by reference, the meaning or definition assigned to
that term in this document shall govern.
While particular arrangements of the present invention have been
illustrated and described, it would be obvious to those skilled in
the art that various other changes and modifications can be made
without departing from the spirit and scope of the invention. It is
therefore intended to cover in the appended claims all such changes
and modifications that are within the scope of this invention.
* * * * *
References